{"drug_name": "Lepirudin", "question": "What is Lepirudin?", "ground_truth_answer": "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.", "ground_truth_context": {"Name": "Lepirudin", "Description": "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor. It is produced in yeast cells and is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease. It is also indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation.", "MoA": "Lepirudin is a direct thrombin inhibitor. It binds to the catalytic and substrate-binding sites of thrombin, forming a stable, irreversible and non-covalent complex. This blocks the protease activity of thrombin and inhibits the coagulation process. It can inhibit thrombin in both its clot-bound or free states.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "Lepirudin is intended for use with aspirin in patients with acute coronary syndromes (ACS).", "Formula": "N/A"}, "rag_answer": "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.", "rag_full_output": {"answer": "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.", "drug_extracted": "Lepirudin", "chunks_used": [{"drug_name": "Lepirudin", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved withdrawn. DESCRIPTION: Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct "}, {"drug_name": "Lepirudin", "type": "general", "preview": ". MECHANISM-OF-ACTION: Lepirudin is a direct thrombin inhibitor used as an anticoagulant in patients for whom heparin is contraindicated.[L41539,A3] Thrombin is a serine protease that participates in "}, {"drug_name": "Lepirudin", "type": "general", "preview": ". This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]. AVERAGE-MASS: 323."}, {"drug_name": "Lepirudin", "type": "general", "preview": ". HALF-LIFE: Lepirudin has an initial half-life of approximately 10 minutes, and in young healthy volunteers, it has a terminal half-time of 1.3 hours.[L41539] Lepirudin has a first-order elimination "}, {"drug_name": "Lepirudin", "type": "general", "preview": ". Its activity is measured by anti-thrombin units (ATUs) that correspond to the amount of lepirudin required to neutralize a unit of the World Health Organization α-thrombin (89/588) standard. The act"}], "num_chunks": 5}}
{"drug_name": "Lepirudin", "question": "What is the mechanism of action of Lepirudin?", "ground_truth_answer": "Lepirudin is a direct thrombin inhibitor that binds to the catalytic and substrate-binding sites of thrombin, forming a stable, irreversible and non-covalent complex, which blocks thrombin's protease activity and inhibits the coagulation process.", "ground_truth_context": {"Name": "Lepirudin", "Description": "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor. It is produced in yeast cells and is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease. It is also indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation.", "MoA": "Lepirudin is a direct thrombin inhibitor. It binds to the catalytic and substrate-binding sites of thrombin, forming a stable, irreversible and non-covalent complex. This blocks the protease activity of thrombin and inhibits the coagulation process. It can inhibit thrombin in both its clot-bound or free states.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "Lepirudin is intended for use with aspirin in patients with acute coronary syndromes (ACS).", "Formula": "N/A"}, "rag_answer": "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.", "rag_full_output": {"answer": "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.", "drug_extracted": "Lepirudin", "chunks_used": [{"drug_name": "Lepirudin", "type": "general", "preview": ". Its activity is measured by anti-thrombin units (ATUs) that correspond to the amount of lepirudin required to neutralize a unit of the World Health Organization α-thrombin (89/588) standard. The act"}, {"drug_name": "Lepirudin", "type": "general", "preview": ". MECHANISM-OF-ACTION: Lepirudin is a direct thrombin inhibitor used as an anticoagulant in patients for whom heparin is contraindicated.[L41539,A3] Thrombin is a serine protease that participates in "}, {"drug_name": "Lepirudin", "type": "general", "preview": ". This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]. AVERAGE-MASS: 323."}, {"drug_name": "Lepirudin", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved withdrawn. DESCRIPTION: Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct "}, {"drug_name": "Lepirudin", "type": "general", "preview": ". HALF-LIFE: Lepirudin has an initial half-life of approximately 10 minutes, and in young healthy volunteers, it has a terminal half-time of 1.3 hours.[L41539] Lepirudin has a first-order elimination "}], "num_chunks": 5}}
{"drug_name": "Lepirudin", "question": "What are the primary indications for Lepirudin?", "ground_truth_answer": "Lepirudin is indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) and for anticoagulation in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease.", "ground_truth_context": {"Name": "Lepirudin", "Description": "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor. It is produced in yeast cells and is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease. It is also indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation.", "MoA": "Lepirudin is a direct thrombin inhibitor. It binds to the catalytic and substrate-binding sites of thrombin, forming a stable, irreversible and non-covalent complex. This blocks the protease activity of thrombin and inhibits the coagulation process. It can inhibit thrombin in both its clot-bound or free states.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "Lepirudin is intended for use with aspirin in patients with acute coronary syndromes (ACS).", "Formula": "N/A"}, "rag_answer": "Lepirudin is indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation.", "rag_full_output": {"answer": "Lepirudin is indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation.", "drug_extracted": "Lepirudin", "chunks_used": [{"drug_name": "Lepirudin", "type": "general", "preview": ". This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]. AVERAGE-MASS: 323."}, {"drug_name": "Lepirudin", "type": "general", "preview": ". Its activity is measured by anti-thrombin units (ATUs) that correspond to the amount of lepirudin required to neutralize a unit of the World Health Organization α-thrombin (89/588) standard. The act"}, {"drug_name": "Lepirudin", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved withdrawn. DESCRIPTION: Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct "}, {"drug_name": "Lepirudin", "type": "general", "preview": ". MECHANISM-OF-ACTION: Lepirudin is a direct thrombin inhibitor used as an anticoagulant in patients for whom heparin is contraindicated.[L41539,A3] Thrombin is a serine protease that participates in "}, {"drug_name": "Lepirudin", "type": "general", "preview": ". HALF-LIFE: Lepirudin has an initial half-life of approximately 10 minutes, and in young healthy volunteers, it has a terminal half-time of 1.3 hours.[L41539] Lepirudin has a first-order elimination "}], "num_chunks": 5}}
{"drug_name": "Lepirudin", "question": "What is the primary target of Lepirudin?", "ground_truth_answer": "The primary target of Lepirudin is thrombin.", "ground_truth_context": {"Name": "Lepirudin", "Description": "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor. It is produced in yeast cells and is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease. It is also indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation.", "MoA": "Lepirudin is a direct thrombin inhibitor. It binds to the catalytic and substrate-binding sites of thrombin, forming a stable, irreversible and non-covalent complex. This blocks the protease activity of thrombin and inhibits the coagulation process. It can inhibit thrombin in both its clot-bound or free states.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "Lepirudin is intended for use with aspirin in patients with acute coronary syndromes (ACS).", "Formula": "N/A"}, "rag_answer": "The primary target of Lepirudin is thrombin.", "rag_full_output": {"answer": "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.", "drug_extracted": "Lepirudin", "chunks_used": [{"drug_name": "Lepirudin", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved withdrawn. DESCRIPTION: Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct "}, {"drug_name": "Lepirudin", "type": "general", "preview": ". Its activity is measured by anti-thrombin units (ATUs) that correspond to the amount of lepirudin required to neutralize a unit of the World Health Organization α-thrombin (89/588) standard. The act"}, {"drug_name": "Lepirudin", "type": "general", "preview": ". This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]. AVERAGE-MASS: 323."}, {"drug_name": "Lepirudin", "type": "general", "preview": ". MECHANISM-OF-ACTION: Lepirudin is a direct thrombin inhibitor used as an anticoagulant in patients for whom heparin is contraindicated.[L41539,A3] Thrombin is a serine protease that participates in "}, {"drug_name": "Lepirudin", "type": "general", "preview": ". HALF-LIFE: Lepirudin has an initial half-life of approximately 10 minutes, and in young healthy volunteers, it has a terminal half-time of 1.3 hours.[L41539] Lepirudin has a first-order elimination "}], "num_chunks": 5}}
{"drug_name": "Lepirudin", "question": "With what other drug is Lepirudin intended for use in patients with acute coronary syndromes?", "ground_truth_answer": "Lepirudin is intended for use with aspirin in patients with acute coronary syndromes.", "ground_truth_context": {"Name": "Lepirudin", "Description": "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor. It is produced in yeast cells and is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease. It is also indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation.", "MoA": "Lepirudin is a direct thrombin inhibitor. It binds to the catalytic and substrate-binding sites of thrombin, forming a stable, irreversible and non-covalent complex. This blocks the protease activity of thrombin and inhibits the coagulation process. It can inhibit thrombin in both its clot-bound or free states.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "Lepirudin is intended for use with aspirin in patients with acute coronary syndromes (ACS).", "Formula": "N/A"}, "rag_answer": "Lepirudin is intended for use with aspirin in patients with acute coronary syndromes.", "rag_full_output": {"answer": "Lepirudin is indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation.", "drug_extracted": "Lepirudin", "chunks_used": [{"drug_name": "Lepirudin", "type": "general", "preview": ". This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]. AVERAGE-MASS: 323."}, {"drug_name": "Lepirudin", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved withdrawn. DESCRIPTION: Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct "}, {"drug_name": "Lepirudin", "type": "general", "preview": ". Its activity is measured by anti-thrombin units (ATUs) that correspond to the amount of lepirudin required to neutralize a unit of the World Health Organization α-thrombin (89/588) standard. The act"}, {"drug_name": "Lepirudin", "type": "general", "preview": ". No saturable effect was observed at the highest tested dose (0.5 mg/kg, IV bolus).[L41539] Thrombin time was considered an unsuitable routine test for lepirudin monitoring due to the high values det"}, {"drug_name": "Lepirudin", "type": "general", "preview": ". ABSORPTION: Lepirudin administered as a single intravenous bolus injection of 0.4 mg/kg in 9 healthy volunteers (male and female) resulted in a C<sub>max</sub> of 2924 ng/mL, a t<sub>max</sub> of 0."}], "num_chunks": 5}}
{"drug_name": "Cetuximab", "question": "What is Cetuximab?", "ground_truth_answer": "Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody.", "ground_truth_context": {"Name": "Cetuximab", "Description": "Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). It is approved for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.", "MoA": "Cetuximab is a monoclonal antibody that binds specifically to the EGFR on both normal and tumour cells to competitively inhibit the binding of epidermal growth factor (EGF) and other ligands. Upon binding to domain III of EGFR, cetuximab prevents the receptor from adopting an extended conformation and thereby inhibits EGFR activation, as well as phosphorylation and activation of receptor-associated kinases (MAPK, PI3K/Akt, Jak/Stat). This inhibition of the EGFR signalling pathway ultimately leads to inhibition of cell cycle progression, cell survival pathways, and tumour cell motility and invasion. Cetuximab also induces cell apoptosis and decreases matrix metalloproteinase and vascular endothelial growth factor (VEGF) production, and results in internalization of the antibody-receptor complex leading to an overall downregulation of EGFR expression.", "Targets": "Epidermal growth factor receptor (EGFR)", "Physical_State": "N/A", "Interactions": "Cetuximab is administered as monotherapy or in combination with other chemotherapies, including platinum agents, radiation therapy, leucovorin, fluorouracil, irinotecan, and encorafenib.", "Formula": "N/A"}, "rag_answer": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "rag_full_output": {"answer": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "drug_extracted": "Cetuximab", "chunks_used": [{"drug_name": "Cetuximab", "type": "general", "preview": ". ATC-CODES: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ANTINEOPLASTIC AGENTS EGFR (Epidermal Growth Factor Receptor) inhibitors. PHARMACODYNAMICS: C"}, {"drug_name": "Cetuximab", "type": "general", "preview": ". AVERAGE-MASS: 323.4. MONOISOTOPIC-MASS: 323.08111356. UNII: PQX0D8J21J. CAS-NUMBER: 205923-56-4. STATE: liquid. DRUG-INTERACTIONS: Rozrolimupab, Sibrotuzumab, Esterified estrogens, Blinatumomab, Eth"}, {"drug_name": "Cetuximab", "type": "general", "preview": ", cetuximab is used for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.[A227963,L39045] It has also"}, {"drug_name": "Cetuximab", "type": "general", "preview": ". It is indicated for recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy.[L30448] Cetuximab is also indicated for K-Ras wild-type, EGFR-expre"}, {"drug_name": "Cetuximab", "type": "general", "preview": ". ABSORPTION: After administration of a 400 mg/m<sup>2</sup> initial dose followed by a 250 mg/m<sup>2</sup> weekly dose, the steady-state levels of cetuximab was reached by the third weekly infusion "}], "num_chunks": 5}}
{"drug_name": "Cetuximab", "question": "What is the mechanism of action of Cetuximab?", "ground_truth_answer": "Cetuximab binds specifically to the EGFR on both normal and tumour cells to competitively inhibit the binding of epidermal growth factor (EGF) and other ligands, thereby inhibiting EGFR activation and downstream signaling pathways.", "ground_truth_context": {"Name": "Cetuximab", "Description": "Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). It is approved for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.", "MoA": "Cetuximab is a monoclonal antibody that binds specifically to the EGFR on both normal and tumour cells to competitively inhibit the binding of epidermal growth factor (EGF) and other ligands. Upon binding to domain III of EGFR, cetuximab prevents the receptor from adopting an extended conformation and thereby inhibits EGFR activation, as well as phosphorylation and activation of receptor-associated kinases (MAPK, PI3K/Akt, Jak/Stat). This inhibition of the EGFR signalling pathway ultimately leads to inhibition of cell cycle progression, cell survival pathways, and tumour cell motility and invasion. Cetuximab also induces cell apoptosis and decreases matrix metalloproteinase and vascular endothelial growth factor (VEGF) production, and results in internalization of the antibody-receptor complex leading to an overall downregulation of EGFR expression.", "Targets": "Epidermal growth factor receptor (EGFR)", "Physical_State": "N/A", "Interactions": "Cetuximab is administered as monotherapy or in combination with other chemotherapies, including platinum agents, radiation therapy, leucovorin, fluorouracil, irinotecan, and encorafenib.", "Formula": "N/A"}, "rag_answer": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "rag_full_output": {"answer": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "drug_extracted": "Cetuximab", "chunks_used": [{"drug_name": "Cetuximab", "type": "general", "preview": ". ATC-CODES: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ANTINEOPLASTIC AGENTS EGFR (Epidermal Growth Factor Receptor) inhibitors. PHARMACODYNAMICS: C"}, {"drug_name": "Cetuximab", "type": "general", "preview": ". This EGFR signalling pathway is often dysregulated in cancer cells, leading to aberrant cell growth and enhanced cell survival.[L31418] Cetuximab is a monoclonal antibody that binds specifically to "}, {"drug_name": "Cetuximab", "type": "general", "preview": ", cetuximab is used for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.[A227963,L39045] It has also"}, {"drug_name": "Cetuximab", "type": "general", "preview": ". ABSORPTION: After administration of a 400 mg/m<sup>2</sup> initial dose followed by a 250 mg/m<sup>2</sup> weekly dose, the steady-state levels of cetuximab was reached by the third weekly infusion "}], "num_chunks": 4}}
{"drug_name": "Cetuximab", "question": "What is the primary target of Cetuximab?", "ground_truth_answer": "The primary target of Cetuximab is the epidermal growth factor receptor (EGFR).", "ground_truth_context": {"Name": "Cetuximab", "Description": "Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). It is approved for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.", "MoA": "Cetuximab is a monoclonal antibody that binds specifically to the EGFR on both normal and tumour cells to competitively inhibit the binding of epidermal growth factor (EGF) and other ligands. Upon binding to domain III of EGFR, cetuximab prevents the receptor from adopting an extended conformation and thereby inhibits EGFR activation, as well as phosphorylation and activation of receptor-associated kinases (MAPK, PI3K/Akt, Jak/Stat). This inhibition of the EGFR signalling pathway ultimately leads to inhibition of cell cycle progression, cell survival pathways, and tumour cell motility and invasion. Cetuximab also induces cell apoptosis and decreases matrix metalloproteinase and vascular endothelial growth factor (VEGF) production, and results in internalization of the antibody-receptor complex leading to an overall downregulation of EGFR expression.", "Targets": "Epidermal growth factor receptor (EGFR)", "Physical_State": "N/A", "Interactions": "Cetuximab is administered as monotherapy or in combination with other chemotherapies, including platinum agents, radiation therapy, leucovorin, fluorouracil, irinotecan, and encorafenib.", "Formula": "N/A"}, "rag_answer": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "rag_full_output": {"answer": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "drug_extracted": "Cetuximab", "chunks_used": [{"drug_name": "Cetuximab", "type": "general", "preview": ", cetuximab is used for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.[A227963,L39045] It has also"}, {"drug_name": "Cetuximab", "type": "general", "preview": ". ATC-CODES: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ANTINEOPLASTIC AGENTS EGFR (Epidermal Growth Factor Receptor) inhibitors. PHARMACODYNAMICS: C"}, {"drug_name": "Cetuximab", "type": "general", "preview": ". This EGFR signalling pathway is often dysregulated in cancer cells, leading to aberrant cell growth and enhanced cell survival.[L31418] Cetuximab is a monoclonal antibody that binds specifically to "}, {"drug_name": "Cetuximab", "type": "general", "preview": ". AVERAGE-MASS: 323.4. MONOISOTOPIC-MASS: 323.08111356. UNII: PQX0D8J21J. CAS-NUMBER: 205923-56-4. STATE: liquid. DRUG-INTERACTIONS: Rozrolimupab, Sibrotuzumab, Esterified estrogens, Blinatumomab, Eth"}, {"drug_name": "Cetuximab", "type": "general", "preview": ". It is indicated for recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy.[L30448] Cetuximab is also indicated for K-Ras wild-type, EGFR-expre"}], "num_chunks": 5}}
{"drug_name": "Cetuximab", "question": "For which conditions is Cetuximab approved?", "ground_truth_answer": "Cetuximab is approved for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.", "ground_truth_context": {"Name": "Cetuximab", "Description": "Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). It is approved for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.", "MoA": "Cetuximab is a monoclonal antibody that binds specifically to the EGFR on both normal and tumour cells to competitively inhibit the binding of epidermal growth factor (EGF) and other ligands. Upon binding to domain III of EGFR, cetuximab prevents the receptor from adopting an extended conformation and thereby inhibits EGFR activation, as well as phosphorylation and activation of receptor-associated kinases (MAPK, PI3K/Akt, Jak/Stat). This inhibition of the EGFR signalling pathway ultimately leads to inhibition of cell cycle progression, cell survival pathways, and tumour cell motility and invasion. Cetuximab also induces cell apoptosis and decreases matrix metalloproteinase and vascular endothelial growth factor (VEGF) production, and results in internalization of the antibody-receptor complex leading to an overall downregulation of EGFR expression.", "Targets": "Epidermal growth factor receptor (EGFR)", "Physical_State": "N/A", "Interactions": "Cetuximab is administered as monotherapy or in combination with other chemotherapies, including platinum agents, radiation therapy, leucovorin, fluorouracil, irinotecan, and encorafenib.", "Formula": "N/A"}, "rag_answer": "Cetuximab is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy.", "rag_full_output": {"answer": "Cetuximab is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy.", "drug_extracted": "Cetuximab", "chunks_used": [{"drug_name": "Cetuximab", "type": "general", "preview": ", cetuximab is used for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.[A227963,L39045] It has also"}, {"drug_name": "Cetuximab", "type": "general", "preview": ". It is indicated for recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy.[L30448] Cetuximab is also indicated for K-Ras wild-type, EGFR-expre"}, {"drug_name": "Cetuximab", "type": "general", "preview": ". AVERAGE-MASS: 323.4. MONOISOTOPIC-MASS: 323.08111356. UNII: PQX0D8J21J. CAS-NUMBER: 205923-56-4. STATE: liquid. DRUG-INTERACTIONS: Rozrolimupab, Sibrotuzumab, Esterified estrogens, Blinatumomab, Eth"}, {"drug_name": "Cetuximab", "type": "general", "preview": ". ABSORPTION: After administration of a 400 mg/m<sup>2</sup> initial dose followed by a 250 mg/m<sup>2</sup> weekly dose, the steady-state levels of cetuximab was reached by the third weekly infusion "}], "num_chunks": 4}}
{"drug_name": "Cetuximab", "question": "With which other therapies can Cetuximab be combined?", "ground_truth_answer": "Cetuximab can be combined with platinum agents, radiation therapy, leucovorin, fluorouracil, irinotecan, and encorafenib.", "ground_truth_context": {"Name": "Cetuximab", "Description": "Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). It is approved for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.", "MoA": "Cetuximab is a monoclonal antibody that binds specifically to the EGFR on both normal and tumour cells to competitively inhibit the binding of epidermal growth factor (EGF) and other ligands. Upon binding to domain III of EGFR, cetuximab prevents the receptor from adopting an extended conformation and thereby inhibits EGFR activation, as well as phosphorylation and activation of receptor-associated kinases (MAPK, PI3K/Akt, Jak/Stat). This inhibition of the EGFR signalling pathway ultimately leads to inhibition of cell cycle progression, cell survival pathways, and tumour cell motility and invasion. Cetuximab also induces cell apoptosis and decreases matrix metalloproteinase and vascular endothelial growth factor (VEGF) production, and results in internalization of the antibody-receptor complex leading to an overall downregulation of EGFR expression.", "Targets": "Epidermal growth factor receptor (EGFR)", "Physical_State": "N/A", "Interactions": "Cetuximab is administered as monotherapy or in combination with other chemotherapies, including platinum agents, radiation therapy, leucovorin, fluorouracil, irinotecan, and encorafenib.", "Formula": "N/A"}, "rag_answer": "Cetuximab is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy.", "rag_full_output": {"answer": "Cetuximab is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy.", "drug_extracted": "Cetuximab", "chunks_used": [{"drug_name": "Cetuximab", "type": "general", "preview": ", cetuximab is used for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.[A227963,L39045] It has also"}, {"drug_name": "Cetuximab", "type": "general", "preview": ". AVERAGE-MASS: 323.4. MONOISOTOPIC-MASS: 323.08111356. UNII: PQX0D8J21J. CAS-NUMBER: 205923-56-4. STATE: liquid. DRUG-INTERACTIONS: Rozrolimupab, Sibrotuzumab, Esterified estrogens, Blinatumomab, Eth"}, {"drug_name": "Cetuximab", "type": "general", "preview": ". On the contrary, cetuximab does not exert its anti-tumour effects on human tumour xenografts lacking EGFR expression.[A227963, L30448] Cetuximab potentiates the cytotoxic effects of chemotherapeutic"}, {"drug_name": "Cetuximab", "type": "general", "preview": ". It is indicated for recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy.[L30448] Cetuximab is also indicated for K-Ras wild-type, EGFR-expre"}, {"drug_name": "Cetuximab", "type": "general", "preview": ". ATC-CODES: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ANTINEOPLASTIC AGENTS EGFR (Epidermal Growth Factor Receptor) inhibitors. PHARMACODYNAMICS: C"}], "num_chunks": 5}}
{"drug_name": "Dornase alfa", "question": "What is Dornase alfa?", "ground_truth_answer": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme.", "ground_truth_context": {"Name": "Dornase alfa", "Description": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. It cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, enzymatic breakdown of extracellular DNA appears to reduce sputum viscosity and viscoelasticity.", "MoA": "Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Its breakdown of extracellular DNA appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction.", "Targets": "Extracellular DNA", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme.", "rag_full_output": {"answer": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme.", "drug_extracted": "Dornase alfa", "chunks_used": [{"drug_name": "Dornase alfa", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically"}, {"drug_name": "Dornase alfa", "type": "general", "preview": ". Bioavailability: mean sputum concentrations of dornase alfa can be measured after 15 minutes. Onset is achieved within 3 to 7 days. Peak concentrations are achieved after 9 days.. METABOLISM: While "}, {"drug_name": "Dornase alfa", "type": "general", "preview": ". These thick secretions contribute both to reduced pulmonary function and to frequent pulmonary infection. Purulent pulmonary secretions of individuals with cystic fibrosis contain very high concentr"}], "num_chunks": 3}}
{"drug_name": "Dornase alfa", "question": "How is Dornase alfa produced?", "ground_truth_answer": "Dornase alfa is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology.", "ground_truth_context": {"Name": "Dornase alfa", "Description": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. It cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, enzymatic breakdown of extracellular DNA appears to reduce sputum viscosity and viscoelasticity.", "MoA": "Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Its breakdown of extracellular DNA appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction.", "Targets": "Extracellular DNA", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Dornase alfa is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology.", "rag_full_output": {"answer": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme.", "drug_extracted": "Dornase alfa", "chunks_used": [{"drug_name": "Dornase alfa", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically"}, {"drug_name": "Dornase alfa", "type": "general", "preview": ". Bioavailability: mean sputum concentrations of dornase alfa can be measured after 15 minutes. Onset is achieved within 3 to 7 days. Peak concentrations are achieved after 9 days.. METABOLISM: While "}, {"drug_name": "Dornase alfa", "type": "general", "preview": ". These thick secretions contribute both to reduced pulmonary function and to frequent pulmonary infection. Purulent pulmonary secretions of individuals with cystic fibrosis contain very high concentr"}], "num_chunks": 3}}
{"drug_name": "Dornase alfa", "question": "What is the mechanism of action of Dornase alfa?", "ground_truth_answer": "Dornase alfa endonucleolytically cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products.", "ground_truth_context": {"Name": "Dornase alfa", "Description": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. It cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, enzymatic breakdown of extracellular DNA appears to reduce sputum viscosity and viscoelasticity.", "MoA": "Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Its breakdown of extracellular DNA appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction.", "Targets": "Extracellular DNA", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme.", "rag_full_output": {"answer": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme.", "drug_extracted": "Dornase alfa", "chunks_used": [{"drug_name": "Dornase alfa", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically"}, {"drug_name": "Dornase alfa", "type": "general", "preview": ". Bioavailability: mean sputum concentrations of dornase alfa can be measured after 15 minutes. Onset is achieved within 3 to 7 days. Peak concentrations are achieved after 9 days.. METABOLISM: While "}, {"drug_name": "Dornase alfa", "type": "general", "preview": ". These thick secretions contribute both to reduced pulmonary function and to frequent pulmonary infection. Purulent pulmonary secretions of individuals with cystic fibrosis contain very high concentr"}], "num_chunks": 3}}
{"drug_name": "Dornase alfa", "question": "What does Dornase alfa target?", "ground_truth_answer": "Dornase alfa targets extracellular DNA.", "ground_truth_context": {"Name": "Dornase alfa", "Description": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. It cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, enzymatic breakdown of extracellular DNA appears to reduce sputum viscosity and viscoelasticity.", "MoA": "Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Its breakdown of extracellular DNA appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction.", "Targets": "Extracellular DNA", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Dornase alfa targets extracellular DNA.", "rag_full_output": {"answer": "Dornase alfa targets extracellular DNA.", "drug_extracted": "Dornase alfa", "chunks_used": [{"drug_name": "Dornase alfa", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically"}, {"drug_name": "Dornase alfa", "type": "general", "preview": ". Bioavailability: mean sputum concentrations of dornase alfa can be measured after 15 minutes. Onset is achieved within 3 to 7 days. Peak concentrations are achieved after 9 days.. METABOLISM: While "}, {"drug_name": "Dornase alfa", "type": "general", "preview": ". These thick secretions contribute both to reduced pulmonary function and to frequent pulmonary infection. Purulent pulmonary secretions of individuals with cystic fibrosis contain very high concentr"}], "num_chunks": 3}}
{"drug_name": "Dornase alfa", "question": "What improves the viscosity and viscoelasticity of purulent sputum in individuals with CF?", "ground_truth_answer": "The breakdown of extracellular DNA by Dornase alfa improves the viscosity and viscoelasticity of purulent sputum in individuals with CF.", "ground_truth_context": {"Name": "Dornase alfa", "Description": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. It cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, enzymatic breakdown of extracellular DNA appears to reduce sputum viscosity and viscoelasticity.", "MoA": "Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Its breakdown of extracellular DNA appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction.", "Targets": "Extracellular DNA", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "The breakdown of extracellular DNA by Dornase alfa improves the viscosity and viscoelasticity of purulent sputum in individuals with CF.", "rag_full_output": {"answer": "Sorry, I cannot provide medical advice.", "drug_extracted": "corticosteroids", "chunks_used": [{"drug_name": "Dexamethasone", "type": "general", "preview": ". PHARMACODYNAMICS: Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals.[A187463] Dexamethasone's duration of action varie"}, {"drug_name": "Ulobetasol", "type": "general", "preview": ". MECHANISM-OF-ACTION: The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation.[A187463]"}, {"drug_name": "Hydrocortisone acetate", "type": "general", "preview": ". It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory o"}, {"drug_name": "Hydrocortisone cypionate", "type": "general", "preview": ". It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory o"}, {"drug_name": "Hydrocortisone phosphate", "type": "general", "preview": ". It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory o"}], "num_chunks": 5}}
{"drug_name": "Denileukin diftitox", "question": "What is Denileukin diftitox?", "ground_truth_answer": "Denileukin diftitox is a recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133).", "ground_truth_context": {"Name": "Denileukin diftitox", "Description": "A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.", "MoA": "Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.", "Targets": "High-affinity IL-2 receptor complex; IL-2 receptor (Tac) subunit", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways.", "rag_full_output": {"answer": "Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways.", "drug_extracted": "Denileukin diftitox", "chunks_used": [{"drug_name": "Mepolizumab", "type": "general", "preview": "TYPE: biotech. CREATED: 2008-03-19. UPDATED: 2022-06-03. GROUPS: approved investigational. DESCRIPTION: Eosinophils are involved in inflammatory immune responses, and prolonged hypereosinophilia (typi"}, {"drug_name": "Dupilumab", "type": "general", "preview": "TYPE: biotech. CREATED: 2016-10-20. UPDATED: 2022-12-01. GROUPS: approved investigational. DESCRIPTION: Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to t"}, {"drug_name": "Mepolizumab", "type": "general", "preview": ". MECHANISM-OF-ACTION: Hypereosinophilia is typically considered as an absolute eosinophil count of 1500/mm<sup>3</sup> or higher and is associated with aberrant immune responses in several conditions"}, {"drug_name": "Filgotinib", "type": "general", "preview": ". INDICATION: Filgotinib is indicated for the treatment of active moderate to severe rheumatoid arthritis alone or in combination with methotrexate.[L16616] Filgotinib is currently reserved for patien"}, {"drug_name": "Secukinumab", "type": "general", "preview": ", IL-10, TNFα, IFN) during chronic inflammation, secukinumab can potentially alter the concentrations of CYP substrate drugs with a narrow therapeutic index.[L39600]"}], "num_chunks": 5}}
{"drug_name": "Denileukin diftitox", "question": "How is Denileukin diftitox produced?", "ground_truth_answer": "It is produced in an E. coli expression system.", "ground_truth_context": {"Name": "Denileukin diftitox", "Description": "A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.", "MoA": "Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.", "Targets": "High-affinity IL-2 receptor complex; IL-2 receptor (Tac) subunit", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways.", "rag_full_output": {"answer": "Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways.", "drug_extracted": "Denileukin diftitox", "chunks_used": [{"drug_name": "Foreskin fibroblast (neonatal)", "type": "general", "preview": ". It is available frozen as a single sheet (2 by 3 inches) for a single application [L2421].. PHARMACODYNAMICS: This physiologically active dermal substitute is a scaffold upon which tissue can grow, "}, {"drug_name": "Darvadstrocel", "type": "general", "preview": ". Its main mode of therapeutic action comes from its immunomodulatory and anti-inflammatory effects, rather than an ability to stimulate tissue regeneration.[A244529] Upon direct injection into the si"}, {"drug_name": "Dupilumab", "type": "general", "preview": "TYPE: biotech. CREATED: 2016-10-20. UPDATED: 2022-12-01. GROUPS: approved investigational. DESCRIPTION: Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to t"}, {"drug_name": "Mepolizumab", "type": "general", "preview": ". MECHANISM-OF-ACTION: Hypereosinophilia is typically considered as an absolute eosinophil count of 1500/mm<sup>3</sup> or higher and is associated with aberrant immune responses in several conditions"}, {"drug_name": "Colchicine", "type": "general", "preview": ". MECHANISM-OF-ACTION: The exact mechanism of action of colchicine has not been fully established, however likely occurs via the downstream inhibition of inflammation caused by tubulin disruption.[A18"}], "num_chunks": 5}}
{"drug_name": "Denileukin diftitox", "question": "What is the mechanism of action of Denileukin diftitox?", "ground_truth_answer": "Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.", "ground_truth_context": {"Name": "Denileukin diftitox", "Description": "A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.", "MoA": "Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.", "Targets": "High-affinity IL-2 receptor complex; IL-2 receptor (Tac) subunit", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Denileukin diftitox binds to the high-affinity IL-2 receptor complex.", "rag_full_output": {"answer": "Diflucortolone performs its action by the induction of lipocortins which are phospholipase A2 inhibitory proteins and sequentially inhibiting the release of arachidonic acid.", "drug_extracted": "Denileukin diftitox", "chunks_used": [{"drug_name": "Anakinra", "type": "general", "preview": ". Since anakinra is approved for this condition under EUA, the drug should only be used when there are no alternative treatment available.[L43927]. MECHANISM-OF-ACTION: Interleukin-1 (IL-1) plays an i"}, {"drug_name": "Filgotinib", "type": "general", "preview": ", which ultimately results in reduced proinflammatory cytokine signaling.[A189165]"}, {"drug_name": "Rivanicline", "type": "general", "preview": ". It effectively inhibits TNF- and LPS-induced IL-8 production in different cell types."}, {"drug_name": "Difluocortolone", "type": "general", "preview": ". MECHANISM-OF-ACTION: Diflucortolone performs its action by the induction of lipocortins which are phospholipase A2 inhibitory proteins and sequentially inhibiting the release of arachidonic acid. Th"}, {"drug_name": "Colchicine", "type": "general", "preview": ". MECHANISM-OF-ACTION: The exact mechanism of action of colchicine has not been fully established, however likely occurs via the downstream inhibition of inflammation caused by tubulin disruption.[A18"}], "num_chunks": 5}}
{"drug_name": "Denileukin diftitox", "question": "What does Denileukin diftitox bind to?", "ground_truth_answer": "Denileukin diftitox binds to the high-affinity IL-2 receptor complex.", "ground_truth_context": {"Name": "Denileukin diftitox", "Description": "A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.", "MoA": "Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.", "Targets": "High-affinity IL-2 receptor complex; IL-2 receptor (Tac) subunit", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Diflucortolone performs its action by the induction of lipocortins which are phospholipase A2 inhibitory proteins and sequentially inhibiting the release of arachidonic acid.", "rag_full_output": {"answer": "Diflucortolone performs its action by the induction of lipocortins which are phospholipase A2 inhibitory proteins and sequentially inhibiting the release of arachidonic acid.", "drug_extracted": "Denileukin diftitox", "chunks_used": [{"drug_name": "Abatacept", "type": "general", "preview": ". The Fc portion of the drug consists of the hinge region, the C<sub>H</sub>2 domain, and the C<sub>H</sub>3 domain of IgG<sub>1</sub>. Although there are multiple pathways and cell types involved in "}, {"drug_name": "Trastuzumab deruxtecan", "type": "general", "preview": ". PROTEIN-BINDING: The Dxd portion of the drug has a plasma protein binding estimated at 97%.[L10842]"}, {"drug_name": "Difluocortolone", "type": "general", "preview": ". MECHANISM-OF-ACTION: Diflucortolone performs its action by the induction of lipocortins which are phospholipase A2 inhibitory proteins and sequentially inhibiting the release of arachidonic acid. Th"}, {"drug_name": "Mepolizumab", "type": "general", "preview": ". MECHANISM-OF-ACTION: Hypereosinophilia is typically considered as an absolute eosinophil count of 1500/mm<sup>3</sup> or higher and is associated with aberrant immune responses in several conditions"}, {"drug_name": "Mepolizumab", "type": "general", "preview": "TYPE: biotech. CREATED: 2008-03-19. UPDATED: 2022-06-03. GROUPS: approved investigational. DESCRIPTION: Eosinophils are involved in inflammatory immune responses, and prolonged hypereosinophilia (typi"}], "num_chunks": 5}}
{"drug_name": "Denileukin diftitox", "question": "Which cells does the diphtheria toxin associated with Ontak selectively kill?", "ground_truth_answer": "The diphtheria toxin associated with Ontak selectively kills the IL-2 bearing cells.", "ground_truth_context": {"Name": "Denileukin diftitox", "Description": "A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.", "MoA": "Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.", "Targets": "High-affinity IL-2 receptor complex; IL-2 receptor (Tac) subunit", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.", "rag_full_output": {"answer": "The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.", "drug_extracted": "diphtheria toxin", "chunks_used": [{"drug_name": "Denileukin diftitox", "type": "general", "preview": ". The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.. ATC-CODES: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS OTHER ANTINEOPLASTIC AGENTS ANTINEOPLASTIC AGENTS Oth"}, {"drug_name": "Moxetumomab pasudotox", "type": "general", "preview": ". This toxin inhibits protein translation which induces an apoptotic state of the high CD22-expressed cancer cell.[A38879] The toxin included in MxP is the _Pseudomonas_ exotoxin A which, after intern"}, {"drug_name": "Botulinum toxin type A", "type": "general", "preview": ". The crystal structure reveals 3 lobes - the light chain, the amino-terminal portion of the heavy chain, and the carboxyl-terminal portion of the heavy chain.[A231854] Botulinum toxin type A blocks n"}, {"drug_name": "Enfortumab vedotin", "type": "general", "preview": ". These two components are joined via a protease-cleavable linker. Enfortumab vedotin binds to cells expressing Nectin-4 and the resulting enfortumab-Nectin-4 complex is internalized into the cell. On"}, {"drug_name": "Abrocitinib", "type": "general", "preview": ". In atopic dermatitis, JAK1 is the therapeutic target of focus as it is involved in the signalling of the γc family of cytokines involved in immune responses and disease pathophysiology, including IL"}], "num_chunks": 5}}
{"drug_name": "Etanercept", "question": "What is Etanercept?", "ground_truth_answer": "Etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.", "ground_truth_context": {"Name": "Etanercept", "Description": "Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. It is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system and consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).", "MoA": "Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation. It is only capable of binding to the active trimeric form of TNF as its binding site is located in the cleft between subunits.", "Targets": "Tumor necrosis factor (TNF) molecules (specifically the active trimeric form).", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis.", "rag_full_output": {"answer": "Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation.", "drug_extracted": "Etanercept", "chunks_used": [{"drug_name": "Etanercept", "type": "general", "preview": ". The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55).[A216522] Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF "}, {"drug_name": "Etanercept", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 ki"}, {"drug_name": "Etanercept", "type": "general", "preview": ". DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Dexamethasone acetate, Upadacitinib, Trazodone, Blinatumomab, Lobeglitazone, Zaltoprofen (...and 930 more). INDICATION: Etanerc"}, {"drug_name": "Etanercept", "type": "general", "preview": ". HALF-LIFE: Etanercept has a mean half-life of elimination of 102 hours in RA patients.[L14862] Population models have shown a mean half-life of 68 hours in healthy adults and 70.7-94.8 hours in pedi"}], "num_chunks": 4}}
{"drug_name": "Etanercept", "question": "How is Etanercept produced?", "ground_truth_answer": "Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system.", "ground_truth_context": {"Name": "Etanercept", "Description": "Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. It is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system and consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).", "MoA": "Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation. It is only capable of binding to the active trimeric form of TNF as its binding site is located in the cleft between subunits.", "Targets": "Tumor necrosis factor (TNF) molecules (specifically the active trimeric form).", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system.", "rag_full_output": {"answer": "Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system.", "drug_extracted": "Etanercept", "chunks_used": [{"drug_name": "Etanercept", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 ki"}, {"drug_name": "Etanercept", "type": "general", "preview": ". The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55).[A216522] Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF "}, {"drug_name": "Etanercept", "type": "general", "preview": ". HALF-LIFE: Etanercept has a mean half-life of elimination of 102 hours in RA patients.[L14862] Population models have shown a mean half-life of 68 hours in healthy adults and 70.7-94.8 hours in pedi"}, {"drug_name": "Etanercept", "type": "general", "preview": ". DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Dexamethasone acetate, Upadacitinib, Trazodone, Blinatumomab, Lobeglitazone, Zaltoprofen (...and 930 more). INDICATION: Etanerc"}], "num_chunks": 4}}
{"drug_name": "Etanercept", "question": "What is the mechanism of action of Etanercept?", "ground_truth_answer": "Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation.", "ground_truth_context": {"Name": "Etanercept", "Description": "Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. It is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system and consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).", "MoA": "Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation. It is only capable of binding to the active trimeric form of TNF as its binding site is located in the cleft between subunits.", "Targets": "Tumor necrosis factor (TNF) molecules (specifically the active trimeric form).", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation.", "rag_full_output": {"answer": "Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation.", "drug_extracted": "etanercept", "chunks_used": [{"drug_name": "Etanercept", "type": "general", "preview": ". The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55).[A216522] Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF "}, {"drug_name": "Etanercept", "type": "general", "preview": ". DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Dexamethasone acetate, Upadacitinib, Trazodone, Blinatumomab, Lobeglitazone, Zaltoprofen (...and 930 more). INDICATION: Etanerc"}, {"drug_name": "Etanercept", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 ki"}, {"drug_name": "Etanercept", "type": "general", "preview": ". HALF-LIFE: Etanercept has a mean half-life of elimination of 102 hours in RA patients.[L14862] Population models have shown a mean half-life of 68 hours in healthy adults and 70.7-94.8 hours in pedi"}], "num_chunks": 4}}
{"drug_name": "Etanercept", "question": "What specific target does Etanercept bind to?", "ground_truth_answer": "Etanercept binds to the active trimeric form of tumor necrosis factor (TNF) molecules.", "ground_truth_context": {"Name": "Etanercept", "Description": "Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. It is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system and consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).", "MoA": "Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation. It is only capable of binding to the active trimeric form of TNF as its binding site is located in the cleft between subunits.", "Targets": "Tumor necrosis factor (TNF) molecules (specifically the active trimeric form).", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Etanercept binds to the p75 TNF receptor.", "rag_full_output": {"answer": "Etanercept binds to the p75 TNF receptor.", "drug_extracted": "etanercept", "chunks_used": [{"drug_name": "Etanercept", "type": "general", "preview": ". The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55).[A216522] Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF "}, {"drug_name": "Etanercept", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 ki"}, {"drug_name": "Etanercept", "type": "general", "preview": ". DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Dexamethasone acetate, Upadacitinib, Trazodone, Blinatumomab, Lobeglitazone, Zaltoprofen (...and 930 more). INDICATION: Etanerc"}, {"drug_name": "Etanercept", "type": "general", "preview": ". HALF-LIFE: Etanercept has a mean half-life of elimination of 102 hours in RA patients.[L14862] Population models have shown a mean half-life of 68 hours in healthy adults and 70.7-94.8 hours in pedi"}], "num_chunks": 4}}
{"drug_name": "Etanercept", "question": "What are some inflammatory conditions Etanercept is used to treat?", "ground_truth_answer": "Etanercept is used to treat or manage rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA), chronic moderate to severe plaque psoriasis, and psoriatic arthritis.", "ground_truth_context": {"Name": "Etanercept", "Description": "Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. It is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system and consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).", "MoA": "Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation. It is only capable of binding to the active trimeric form of TNF as its binding site is located in the cleft between subunits.", "Targets": "Tumor necrosis factor (TNF) molecules (specifically the active trimeric form).", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older.", "rag_full_output": {"answer": "Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older.", "drug_extracted": "ETANERJET", "chunks_used": [{"drug_name": "Etanercept", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 ki"}, {"drug_name": "Etanercept", "type": "general", "preview": ". DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Dexamethasone acetate, Upadacitinib, Trazodone, Blinatumomab, Lobeglitazone, Zaltoprofen (...and 930 more). INDICATION: Etanerc"}, {"drug_name": "Triamcinolone", "type": "general", "preview": ", keloids, necrobiosis lipoidica diabeticorum, and tumors of an aponeurosis or tendon.[L8252] This formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma"}, {"drug_name": "Etanercept", "type": "general", "preview": ". The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55).[A216522] Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF "}, {"drug_name": "Beclomethasone dipropionate", "type": "general", "preview": ". The aerosol form of beclomethasone diproprionate is not indicated for the relief of acute bronchospasm.[L6871] Indicated for intranasal use to relieve the symptoms of seasonal or perennial allergic "}], "num_chunks": 5}}
{"drug_name": "Bivalirudin", "question": "What type of compound is Bivalirudin?", "ground_truth_answer": "Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor).", "ground_truth_context": {"Name": "Bivalirudin", "Description": "Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously.", "MoA": "Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor).", "rag_full_output": {"answer": "Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin.", "drug_extracted": "Bivalirudin", "chunks_used": [{"drug_name": "Bivalirudin", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhib"}, {"drug_name": "Bivalirudin", "type": "general", "preview": ". PROTEIN-BINDING: Other than thrombin and red blood cells, bivalirudin does not bind to plasma proteins."}], "num_chunks": 2}}
{"drug_name": "Bivalirudin", "question": "How is Bivalirudin administered?", "ground_truth_answer": "Bivalirudin is administered intravenously.", "ground_truth_context": {"Name": "Bivalirudin", "Description": "Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously.", "MoA": "Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Bivalirudin is administered intravenously.", "rag_full_output": {"answer": "Bivalirudin is administered intravenously.", "drug_extracted": "Bivalirudin", "chunks_used": [{"drug_name": "Bivalirudin", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhib"}, {"drug_name": "Bivalirudin", "type": "general", "preview": ". PHARMACODYNAMICS: Bivalirudin mediates an inhibitory action on thrombin by directly and specifically binding to both the catalytic site and anion-binding exosite of circulating and clot-bound thromb"}], "num_chunks": 2}}
{"drug_name": "Bivalirudin", "question": "What is the mechanism of action of Bivalirudin?", "ground_truth_answer": "Bivalirudin inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite.", "ground_truth_context": {"Name": "Bivalirudin", "Description": "Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously.", "MoA": "Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Bivalirudin inhibits the action of thrombin by binding both to its catalytic.", "rag_full_output": {"answer": "Bivalirudin mediates an inhibitory action on thrombin by directly and specifically binding to both the catalytic site and anion-binding exosite of circulating and clot-bound thrombin.", "drug_extracted": "bivalirudin", "chunks_used": [{"drug_name": "Bivalirudin", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhib"}, {"drug_name": "Bivalirudin", "type": "general", "preview": ". PHARMACODYNAMICS: Bivalirudin mediates an inhibitory action on thrombin by directly and specifically binding to both the catalytic site and anion-binding exosite of circulating and clot-bound thromb"}, {"drug_name": "Bivalirudin", "type": "general", "preview": ". Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segme"}, {"drug_name": "Bivalirudin", "type": "general", "preview": ". PROTEIN-BINDING: Other than thrombin and red blood cells, bivalirudin does not bind to plasma proteins."}], "num_chunks": 4}}
{"drug_name": "Bivalirudin", "question": "What is the primary target of Bivalirudin?", "ground_truth_answer": "The primary target of Bivalirudin is thrombin.", "ground_truth_context": {"Name": "Bivalirudin", "Description": "Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously.", "MoA": "Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "The primary target of Bivalirudin is thrombin.", "rag_full_output": {"answer": "Bivalirudin mediates an inhibitory action on thrombin by directly and specifically binding to both the catalytic site and anion-binding exosite of circulating and clot-bound thrombin.", "drug_extracted": "Bivalirudin", "chunks_used": [{"drug_name": "Bivalirudin", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhib"}, {"drug_name": "Bivalirudin", "type": "general", "preview": ". PHARMACODYNAMICS: Bivalirudin mediates an inhibitory action on thrombin by directly and specifically binding to both the catalytic site and anion-binding exosite of circulating and clot-bound thromb"}, {"drug_name": "Bivalirudin", "type": "general", "preview": ". PROTEIN-BINDING: Other than thrombin and red blood cells, bivalirudin does not bind to plasma proteins."}], "num_chunks": 3}}
{"drug_name": "Bivalirudin", "question": "What crucial step in thrombus formation does thrombin facilitate?", "ground_truth_answer": "Thrombin activates fibrinogen into fibrin, which is the crucial step in the formation of thrombus.", "ground_truth_context": {"Name": "Bivalirudin", "Description": "Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously.", "MoA": "Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Thrombin activates fibrinogen into fibrin, which is the crucial step in the formation of thrombus.", "rag_full_output": {"answer": "Thrombin facilitates the conversion of fibrinogen to fibrin.", "drug_extracted": "thrombin", "chunks_used": [{"drug_name": "Thrombin", "type": "general", "preview": ". INDICATION: Bovine thrombin is a topical thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by sta"}, {"drug_name": "Thrombin", "type": "general", "preview": "TYPE: biotech. CREATED: 2015-12-03. UPDATED: 2021-05-21. GROUPS: approved investigational. DESCRIPTION: Also known as coagulation factor II, thrombin is a serine protease that plays a physiological ro"}, {"drug_name": "Human thrombin", "type": "general", "preview": ". MECHANISM-OF-ACTION: Human thrombin (coagulation factor IIa) is a highly specific protease that transforms plasma fibrinogen into fibrin which, in the presence of clotting factor XIII in the patient"}, {"drug_name": "rhThrombin", "type": "general", "preview": ". AVERAGE-MASS: 323.4. MONOISOTOPIC-MASS: 323.08111356. CAS-NUMBER: 1270043-60-1. STATE: solid. INDICATION: Investigated for use/treatment in blood (blood forming organ disorders, unspecified) and hem"}], "num_chunks": 4}}
{"drug_name": "Leuprolide", "question": "What type of compound is Leuprolide?", "ground_truth_answer": "Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH).", "ground_truth_context": {"Name": "Leuprolide", "Description": "Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH) that contains a single D-amino acid (D-leucyl) residue, which increases its circulating half-life to approximately three hours. It binds to the GnRH receptor (GnRHR) and induces downstream modulation of gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, providing clinical efficacy in conditions like advanced prostate cancer, endometriosis, and central precocious puberty. It was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron™.", "MoA": "As a GnRHR agonist, leuprolide initially activates downstream LH and FSH release. After 2-4 weeks of continuous GnRHR stimulation, it results in feedback inhibition and significant downregulation of LH, FSH, and their corresponding downstream effects, producing a therapeutic benefit. These effects are reversible upon treatment discontinuation.", "Targets": "Gonadotropin-releasing hormone receptor (GnRHR)", "Physical_State": "Injectable solution for subcutaneous and intramuscular administration", "Interactions": "Can be used in combination with oral norethisterone for the initial treatment of endometriosis symptoms. It can also be combined with iron supplementation for the preoperative hematological improvement of anemic patients with uterine leiomyomata.", "Formula": "N/A"}, "rag_answer": "An unsaturated, essential fatty acid.", "rag_full_output": {"answer": "An unsaturated, essential fatty acid.", "drug_extracted": "Leuprolide", "chunks_used": [{"drug_name": "Arachidonic Acid", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2021-06-12. GROUPS: experimental. DESCRIPTION: An unsaturated, essential fatty acid. It is found in animal and human fat as well as in the liver, br"}, {"drug_name": "Lawsone", "type": "general", "preview": "TYPE: small molecule. CREATED: 2007-09-11. UPDATED: 2020-06-12. GROUPS: experimental. AVERAGE-MASS: 174.1528. MONOISOTOPIC-MASS: 174.031694058. UNII: TLH4A6LV1W. CAS-NUMBER: 83-72-7. STATE: solid. PDB"}, {"drug_name": "Salicylhydroxamic Acid", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2020-06-12. GROUPS: experimental. AVERAGE-MASS: 153.1354. MONOISOTOPIC-MASS: 153.042593095. UNII: 8Q07182D0T. CAS-NUMBER: 89-73-6. STATE: solid. PDB"}, {"drug_name": "4-Oxoretinol", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2020-08-01. GROUPS: experimental. AVERAGE-MASS: 300.4351. MONOISOTOPIC-MASS: 300.20893014. UNII: 6FFM6M3NPT. CAS-NUMBER: 62702-55-0. STATE: solid. P"}, {"drug_name": "7-Deazaguanine", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2020-06-12. GROUPS: experimental. AVERAGE-MASS: 150.138. MONOISOTOPIC-MASS: 150.054160834. UNII: GPL8T5ZO3M. CAS-NUMBER: 7355-55-7. STATE: solid. PD"}], "num_chunks": 5}}
{"drug_name": "Leuprolide", "question": "What is the primary target of Leuprolide?", "ground_truth_answer": "Leuprolide primarily targets the Gonadotropin-releasing hormone receptor (GnRHR).", "ground_truth_context": {"Name": "Leuprolide", "Description": "Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH) that contains a single D-amino acid (D-leucyl) residue, which increases its circulating half-life to approximately three hours. It binds to the GnRH receptor (GnRHR) and induces downstream modulation of gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, providing clinical efficacy in conditions like advanced prostate cancer, endometriosis, and central precocious puberty. It was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron™.", "MoA": "As a GnRHR agonist, leuprolide initially activates downstream LH and FSH release. After 2-4 weeks of continuous GnRHR stimulation, it results in feedback inhibition and significant downregulation of LH, FSH, and their corresponding downstream effects, producing a therapeutic benefit. These effects are reversible upon treatment discontinuation.", "Targets": "Gonadotropin-releasing hormone receptor (GnRHR)", "Physical_State": "Injectable solution for subcutaneous and intramuscular administration", "Interactions": "Can be used in combination with oral norethisterone for the initial treatment of endometriosis symptoms. It can also be combined with iron supplementation for the preoperative hematological improvement of anemic patients with uterine leiomyomata.", "Formula": "N/A"}, "rag_answer": "Leuprolide primarily targets the Gonadotropin-releasing hormone receptor (GnRHR).", "rag_full_output": {"answer": "Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH).", "drug_extracted": "Leuprolide", "chunks_used": [{"drug_name": "Leuprolide", "type": "general", "preview": ". INDICATION: Leuprolide is indicated for the treatment of advanced prostate cancer [L13781, L34415] and as palliative treatment of advanced prostate cancer.[L13790] It is also used for the treatment "}, {"drug_name": "Leuprolide", "type": "general", "preview": ". Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including adv"}, {"drug_name": "Leuprolide", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (G"}, {"drug_name": "Leuprolide", "type": "general", "preview": ". GnRH binds to corresponding receptors (GnRHRs) on the anterior pituitary gonadotropes, which in turn release luteinizing hormone (LH) and follicle-stimulating hormone (FSH); these, in turn, affect t"}, {"drug_name": "Leuprolide", "type": "general", "preview": ". In addition, Leuprolide may cause convulsions and embryo-fetal toxicity.[L13781, L13790] In pediatric patients undergoing treatment for central precocious puberty (CPP), the initial steroidal spike "}], "num_chunks": 5}}
{"drug_name": "Leuprolide", "question": "When was Leuprolide first approved and what was its original tradename?", "ground_truth_answer": "Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron™.", "ground_truth_context": {"Name": "Leuprolide", "Description": "Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH) that contains a single D-amino acid (D-leucyl) residue, which increases its circulating half-life to approximately three hours. It binds to the GnRH receptor (GnRHR) and induces downstream modulation of gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, providing clinical efficacy in conditions like advanced prostate cancer, endometriosis, and central precocious puberty. It was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron™.", "MoA": "As a GnRHR agonist, leuprolide initially activates downstream LH and FSH release. After 2-4 weeks of continuous GnRHR stimulation, it results in feedback inhibition and significant downregulation of LH, FSH, and their corresponding downstream effects, producing a therapeutic benefit. These effects are reversible upon treatment discontinuation.", "Targets": "Gonadotropin-releasing hormone receptor (GnRHR)", "Physical_State": "Injectable solution for subcutaneous and intramuscular administration", "Interactions": "Can be used in combination with oral norethisterone for the initial treatment of endometriosis symptoms. It can also be combined with iron supplementation for the preoperative hematological improvement of anemic patients with uterine leiomyomata.", "Formula": "N/A"}, "rag_answer": "Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron™.", "rag_full_output": {"answer": "Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron™.", "drug_extracted": "Leuprolide", "chunks_used": [{"drug_name": "Leuprolide", "type": "general", "preview": ". Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including adv"}, {"drug_name": "Leuprolide", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (G"}, {"drug_name": "Leuprolide", "type": "general", "preview": ". INDICATION: Leuprolide is indicated for the treatment of advanced prostate cancer [L13781, L34415] and as palliative treatment of advanced prostate cancer.[L13790] It is also used for the treatment "}, {"drug_name": "Leuprolide", "type": "general", "preview": ". In addition, Leuprolide may cause convulsions and embryo-fetal toxicity.[L13781, L13790] In pediatric patients undergoing treatment for central precocious puberty (CPP), the initial steroidal spike "}], "num_chunks": 4}}
{"drug_name": "Leuprolide", "question": "How does Leuprolide achieve its therapeutic benefit?", "ground_truth_answer": "After 2-4 weeks of continuous GnRHR stimulation, leuprolide causes feedback inhibition and significant downregulation of LH, FSH, and their corresponding downstream effects, producing a therapeutic benefit.", "ground_truth_context": {"Name": "Leuprolide", "Description": "Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH) that contains a single D-amino acid (D-leucyl) residue, which increases its circulating half-life to approximately three hours. It binds to the GnRH receptor (GnRHR) and induces downstream modulation of gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, providing clinical efficacy in conditions like advanced prostate cancer, endometriosis, and central precocious puberty. It was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron™.", "MoA": "As a GnRHR agonist, leuprolide initially activates downstream LH and FSH release. After 2-4 weeks of continuous GnRHR stimulation, it results in feedback inhibition and significant downregulation of LH, FSH, and their corresponding downstream effects, producing a therapeutic benefit. These effects are reversible upon treatment discontinuation.", "Targets": "Gonadotropin-releasing hormone receptor (GnRHR)", "Physical_State": "Injectable solution for subcutaneous and intramuscular administration", "Interactions": "Can be used in combination with oral norethisterone for the initial treatment of endometriosis symptoms. It can also be combined with iron supplementation for the preoperative hematological improvement of anemic patients with uterine leiomyomata.", "Formula": "N/A"}, "rag_answer": "Leuprolide is a gonadotropin-releasing hormone (GnRH) analogue that functions as a GnRH receptor superagonist.", "rag_full_output": {"answer": "Leuprolide is a gonadotropin-releasing hormone (GnRH) analogue that functions as a GnRH receptor superagonist.", "drug_extracted": "Leuprolide", "chunks_used": [{"drug_name": "Leuprolide", "type": "general", "preview": ". Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including adv"}, {"drug_name": "Leuprolide", "type": "general", "preview": ". These effects are reversible upon treatment discontinuation.[A203126, A203129, A203132, A203222, L10310, L13781, L13784, L13787, L13790, L13814]. ATC-CODES: ANTINEOPLASTIC AND IMMUNOMODULATING AGENT"}, {"drug_name": "Leuprolide", "type": "general", "preview": ". INDICATION: Leuprolide is indicated for the treatment of advanced prostate cancer [L13781, L34415] and as palliative treatment of advanced prostate cancer.[L13790] It is also used for the treatment "}, {"drug_name": "Leuprolide", "type": "general", "preview": ". The initial increase in estradiol levels may worsen symptoms such as pain and bleeding. Long-term use of leuprolide is associated with loss of bone mineral density. Patients co-administered with [no"}, {"drug_name": "Leuprolide", "type": "general", "preview": ". GnRH binds to corresponding receptors (GnRHRs) on the anterior pituitary gonadotropes, which in turn release luteinizing hormone (LH) and follicle-stimulating hormone (FSH); these, in turn, affect t"}], "num_chunks": 5}}
{"drug_name": "Leuprolide", "question": "For which conditions is Leuprolide indicated?", "ground_truth_answer": "Leuprolide is indicated for the treatment of advanced prostate cancer, central precocious puberty, initial treatment of endometriosis symptoms (in combination with oral norethisterone), and preoperative hematological improvement of anemic patients with uterine leiomyomata (in combination with iron supplementation).", "ground_truth_context": {"Name": "Leuprolide", "Description": "Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH) that contains a single D-amino acid (D-leucyl) residue, which increases its circulating half-life to approximately three hours. It binds to the GnRH receptor (GnRHR) and induces downstream modulation of gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, providing clinical efficacy in conditions like advanced prostate cancer, endometriosis, and central precocious puberty. It was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron™.", "MoA": "As a GnRHR agonist, leuprolide initially activates downstream LH and FSH release. After 2-4 weeks of continuous GnRHR stimulation, it results in feedback inhibition and significant downregulation of LH, FSH, and their corresponding downstream effects, producing a therapeutic benefit. These effects are reversible upon treatment discontinuation.", "Targets": "Gonadotropin-releasing hormone receptor (GnRHR)", "Physical_State": "Injectable solution for subcutaneous and intramuscular administration", "Interactions": "Can be used in combination with oral norethisterone for the initial treatment of endometriosis symptoms. It can also be combined with iron supplementation for the preoperative hematological improvement of anemic patients with uterine leiomyomata.", "Formula": "N/A"}, "rag_answer": "Leuprolide is indicated for the treatment of advanced prostate cancer [L13781, L34415] and as palliative treatment of advanced prostate cancer.[L13790]", "rag_full_output": {"answer": "Leuprolide is indicated for the treatment of advanced prostate cancer [L13781, L34415] and as palliative treatment of advanced prostate cancer.[L13790]", "drug_extracted": "Leuprolide", "chunks_used": [{"drug_name": "Leuprolide", "type": "general", "preview": ". INDICATION: Leuprolide is indicated for the treatment of advanced prostate cancer [L13781, L34415] and as palliative treatment of advanced prostate cancer.[L13790] It is also used for the treatment "}, {"drug_name": "Leuprolide", "type": "general", "preview": ". The initial increase in estradiol levels may worsen symptoms such as pain and bleeding. Long-term use of leuprolide is associated with loss of bone mineral density. Patients co-administered with [no"}, {"drug_name": "Leuprolide", "type": "general", "preview": ". Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including adv"}, {"drug_name": "Leuprolide", "type": "general", "preview": ". In addition, Leuprolide may cause convulsions and embryo-fetal toxicity.[L13781, L13790] In pediatric patients undergoing treatment for central precocious puberty (CPP), the initial steroidal spike "}, {"drug_name": "Leuprolide", "type": "general", "preview": ". These effects are reversible upon treatment discontinuation.[A203126, A203129, A203132, A203222, L10310, L13781, L13784, L13787, L13790, L13814]. ATC-CODES: ANTINEOPLASTIC AND IMMUNOMODULATING AGENT"}], "num_chunks": 5}}
{"drug_name": "Peginterferon alfa-2a", "question": "What is Peginterferon alfa-2a?", "ground_truth_answer": "Peginterferon alfa-2a is a form of recombinant interferon derived from the alfa-2a moiety of recombinant human interferon.", "ground_truth_context": {"Name": "Peginterferon alfa-2a", "Description": "Peginterferon alfa-2a is a form of recombinant interferon derived from the alfa-2a moiety of recombinant human interferon, historically used as part of combination therapy to treat chronic Hepatitis C and also indicated as a monotherapy for adult patients with chronic hepatitis B infection.", "MoA": "Peginterferon alfa-2a binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response.", "Targets": "Human type 1 interferon receptors", "Physical_State": "Available as a fixed dose injector (tradename Pegasys)", "Interactions": "Used alongside [DB00811] (e.g., ribavirin) or other antiviral drugs for Hepatitis C.", "Formula": "N/A"}, "rag_answer": "Peginterferon alfa-2a is a form of recombinant interferon derived from the alfa-2a.", "rag_full_output": {"answer": "Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).", "drug_extracted": "peginterferon alfa-2", "chunks_used": [{"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000661, BE0000385. DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Upadacitinib, Blinatumomab, Ethyl chloride, Tacrine, Triflusal, Doxepin (...and 6"}, {"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic H"}, {"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000661, BE0000385. DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Upadacitinib, Trazodone, Blinatumomab, Zaltoprofen, Tacrine, Triflusal (...and 85"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": ". Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Use of P"}], "num_chunks": 5}}
{"drug_name": "Peginterferon alfa-2a", "question": "What is the mechanism of action of Peginterferon alfa-2a?", "ground_truth_answer": "Peginterferon alfa-2a binds to and activates human type 1 interferon receptors causing them to dimerize, which activates the JAK/STAT pathway to increase expression of genes involved in the innate antiviral response.", "ground_truth_context": {"Name": "Peginterferon alfa-2a", "Description": "Peginterferon alfa-2a is a form of recombinant interferon derived from the alfa-2a moiety of recombinant human interferon, historically used as part of combination therapy to treat chronic Hepatitis C and also indicated as a monotherapy for adult patients with chronic hepatitis B infection.", "MoA": "Peginterferon alfa-2a binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response.", "Targets": "Human type 1 interferon receptors", "Physical_State": "Available as a fixed dose injector (tradename Pegasys)", "Interactions": "Used alongside [DB00811] (e.g., ribavirin) or other antiviral drugs for Hepatitis C.", "Formula": "N/A"}, "rag_answer": "Peginterferon alfa-2a is derived from recombinant human interferon's alfa-2a moeity [FDA Label]. It binds to and activates human type 1 interferon receptors causing them to dimerize.", "rag_full_output": {"answer": "Peginterferon alfa-2a is derived from recombinant human interferon's alfa-2a moeity [FDA Label]. It binds to and activates human type 1 interferon receptors causing them to dimerize.", "drug_extracted": "peginterferon alfa-2", "chunks_used": [{"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000661, BE0000385. DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Upadacitinib, Blinatumomab, Ethyl chloride, Tacrine, Triflusal, Doxepin (...and 6"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to"}, {"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000661, BE0000385. DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Upadacitinib, Trazodone, Blinatumomab, Zaltoprofen, Tacrine, Triflusal (...and 85"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": ". Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Use of P"}, {"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic H"}], "num_chunks": 5}}
{"drug_name": "Peginterferon alfa-2a", "question": "What are the primary targets of Peginterferon alfa-2a?", "ground_truth_answer": "The primary targets of Peginterferon alfa-2a are human type 1 interferon receptors.", "ground_truth_context": {"Name": "Peginterferon alfa-2a", "Description": "Peginterferon alfa-2a is a form of recombinant interferon derived from the alfa-2a moiety of recombinant human interferon, historically used as part of combination therapy to treat chronic Hepatitis C and also indicated as a monotherapy for adult patients with chronic hepatitis B infection.", "MoA": "Peginterferon alfa-2a binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response.", "Targets": "Human type 1 interferon receptors", "Physical_State": "Available as a fixed dose injector (tradename Pegasys)", "Interactions": "Used alongside [DB00811] (e.g., ribavirin) or other antiviral drugs for Hepatitis C.", "Formula": "N/A"}, "rag_answer": "Peginterferon alfa-2a is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label].", "rag_full_output": {"answer": "Peginterferon alfa-2a is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label].", "drug_extracted": "peginterferon alfa-2", "chunks_used": [{"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000661, BE0000385. DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Upadacitinib, Blinatumomab, Ethyl chloride, Tacrine, Triflusal, Doxepin (...and 6"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to"}, {"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000661, BE0000385. DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Upadacitinib, Trazodone, Blinatumomab, Zaltoprofen, Tacrine, Triflusal (...and 85"}, {"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic H"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": ". Peginterferon alfa-2a was used alongside [DB00811] with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of therapy. SVR and eradication of HCV infection is associ"}], "num_chunks": 5}}
{"drug_name": "Peginterferon alfa-2a", "question": "For which conditions is Peginterferon alfa-2a indicated?", "ground_truth_answer": "Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs and as a monotherapy for adult patients with chronic hepatitis B infection.", "ground_truth_context": {"Name": "Peginterferon alfa-2a", "Description": "Peginterferon alfa-2a is a form of recombinant interferon derived from the alfa-2a moiety of recombinant human interferon, historically used as part of combination therapy to treat chronic Hepatitis C and also indicated as a monotherapy for adult patients with chronic hepatitis B infection.", "MoA": "Peginterferon alfa-2a binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response.", "Targets": "Human type 1 interferon receptors", "Physical_State": "Available as a fixed dose injector (tradename Pegasys)", "Interactions": "Used alongside [DB00811] (e.g., ribavirin) or other antiviral drugs for Hepatitis C.", "Formula": "N/A"}, "rag_answer": "Peginterferon alfa-2a is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label].", "rag_full_output": {"answer": "Peginterferon alfa-2a is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label].", "drug_extracted": "peginterferon alfa-2", "chunks_used": [{"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000661, BE0000385. DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Upadacitinib, Blinatumomab, Ethyl chloride, Tacrine, Triflusal, Doxepin (...and 6"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": ". Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Use of P"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": ". Peginterferon alfa-2a was used alongside [DB00811] with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of therapy. SVR and eradication of HCV infection is associ"}, {"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000661, BE0000385. DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Upadacitinib, Trazodone, Blinatumomab, Zaltoprofen, Tacrine, Triflusal (...and 85"}], "num_chunks": 5}}
{"drug_name": "Peginterferon alfa-2a", "question": "What is the tradename under which Peginterferon alfa-2a is available as a fixed dose injector?", "ground_truth_answer": "Peginterferon alfa-2a is available as a fixed dose injector under the tradename Pegasys.", "ground_truth_context": {"Name": "Peginterferon alfa-2a", "Description": "Peginterferon alfa-2a is a form of recombinant interferon derived from the alfa-2a moiety of recombinant human interferon, historically used as part of combination therapy to treat chronic Hepatitis C and also indicated as a monotherapy for adult patients with chronic hepatitis B infection.", "MoA": "Peginterferon alfa-2a binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response.", "Targets": "Human type 1 interferon receptors", "Physical_State": "Available as a fixed dose injector (tradename Pegasys)", "Interactions": "Used alongside [DB00811] (e.g., ribavirin) or other antiviral drugs for Hepatitis C.", "Formula": "N/A"}, "rag_answer": "Peginterferon alfa-2a is available as a fixed dose injector (tradename Pegasys) used for the treatment of chronic Hepatitis C.", "rag_full_output": {"answer": "Peginterferon alfa-2a is available as a fixed dose injector (tradename Pegasys) used for the treatment of chronic Hepatitis C.", "drug_extracted": "peginterferon alfa-2", "chunks_used": [{"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": ". Peginterferon alfa-2a was used alongside [DB00811] with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of therapy. SVR and eradication of HCV infection is associ"}, {"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": ". Peginterferon alfa-2b was used alongside [DB00811] with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of therapy. SVR and eradication of HCV infection is associ"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000661, BE0000385. DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Upadacitinib, Blinatumomab, Ethyl chloride, Tacrine, Triflusal, Doxepin (...and 6"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": ". Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Use of P"}], "num_chunks": 5}}
{"drug_name": "Alteplase", "question": "What type of drug is Alteplase?", "ground_truth_answer": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent.", "ground_truth_context": {"Name": "Alteplase", "Description": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells. It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).", "MoA": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) that converts plasminogen to plasmin in a fibrin-dependent process. In the presence of fibrin clots, alteplase binds to fibrin and cleaves the arginine-valine bond at positions 560 and 561 of plasminogen, converting it into its active form, plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus and promotes clot dissolution. Alteplase initiates local fibrinolysis with limited systemic proteolysis.", "Targets": "Plasminogen, Fibrin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent.", "rag_full_output": {"answer": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent.", "drug_extracted": "tissue plasminogen activator", "chunks_used": [{"drug_name": "Alteplase", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent.[L4"}, {"drug_name": "Alteplase", "type": "general", "preview": ". ATC-CODES: OPHTHALMOLOGICALS OTHER OPHTHALMOLOGICALS SENSORY ORGANS Enzymes Other ophthalmologicals ANTITHROMBOTIC AGENTS BLOOD AND BLOOD FORMING ORGANS. PHARMACODYNAMICS: Alteplase binds to fibrin "}, {"drug_name": "Alteplase", "type": "general", "preview": ". Alteplase is also indicated for the lysis of acute massive pulmonary embolism, defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments, and acute pulmonary embol"}, {"drug_name": "MLN576", "type": "general", "preview": "TYPE: small molecule. CREATED: 2008-03-19. UPDATED: 2021-05-05. GROUPS: investigational. DESCRIPTION: XR11576 (MLN576) is a novel monophenazine with a mechanism of action that includes interaction wit"}, {"drug_name": "Fenethylline", "type": "general", "preview": "TYPE: small molecule. CREATED: 2007-07-31. UPDATED: 2020-06-12. GROUPS: experimental. DESCRIPTION: endoplasmic reticulum membrane. AVERAGE-MASS: 341.415. MONOISOTOPIC-MASS: 341.185175001. UNII: YZ0N7V"}], "num_chunks": 5}}
{"drug_name": "Alteplase", "question": "How does Alteplase convert plasminogen to plasmin?", "ground_truth_answer": "In the presence of fibrin clots, alteplase binds to fibrin and cleaves the arginine-valine bond at positions 560 and 561 of plasminogen, converting it into its active form, plasmin.", "ground_truth_context": {"Name": "Alteplase", "Description": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells. It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).", "MoA": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) that converts plasminogen to plasmin in a fibrin-dependent process. In the presence of fibrin clots, alteplase binds to fibrin and cleaves the arginine-valine bond at positions 560 and 561 of plasminogen, converting it into its active form, plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus and promotes clot dissolution. Alteplase initiates local fibrinolysis with limited systemic proteolysis.", "Targets": "Plasminogen, Fibrin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as [fibrinolysin] - as part of the fibrinolytic pathway that breaks down fibrin blood clots.", "rag_full_output": {"answer": "Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as [fibrinolysin] - as part of the fibrinolytic pathway that breaks down fibrin blood clots.", "drug_extracted": "Plasmin", "chunks_used": [{"drug_name": "Plasminogen", "type": "general", "preview": "TYPE: biotech. CREATED: 2021-06-17. UPDATED: 2021-06-22. GROUPS: approved. DESCRIPTION: Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as [fibrinolysin] - a"}, {"drug_name": "Plasminogen", "type": "general", "preview": ". ABSORPTION: Following 12 weeks of intravenous administration every 2 to 4 days, the mean AUC<sub>inf</sub> of Ryplazim was 5731.8 hr*% and its C<sub>max</sub> was approximately 125% of the mean phys"}], "num_chunks": 2}}
{"drug_name": "Alteplase", "question": "What are the molecular targets of Alteplase?", "ground_truth_answer": "Alteplase targets plasminogen and fibrin.", "ground_truth_context": {"Name": "Alteplase", "Description": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells. It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).", "MoA": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) that converts plasminogen to plasmin in a fibrin-dependent process. In the presence of fibrin clots, alteplase binds to fibrin and cleaves the arginine-valine bond at positions 560 and 561 of plasminogen, converting it into its active form, plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus and promotes clot dissolution. Alteplase initiates local fibrinolysis with limited systemic proteolysis.", "Targets": "Plasminogen, Fibrin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Alteplase has the following targets: BE0002742.", "rag_full_output": {"answer": "Alteplase has the following targets: BE0002742.", "drug_extracted": "Alteplase", "chunks_used": [{"drug_name": "N-Valeric Acid", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2020-07-02. GROUPS: experimental. DESCRIPTION: hydrolase activity. AVERAGE-MASS: 102.1317. MONOISOTOPIC-MASS: 102.068079564. UNII: GZK92PJM7B. CAS-N"}, {"drug_name": "S-Hexylglutathione", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2020-06-12. GROUPS: experimental. DESCRIPTION: cytoplasm. AVERAGE-MASS: 391.483. MONOISOTOPIC-MASS: 391.177706365. UNII: M73SNN908F. CAS-NUMBER: 244"}, {"drug_name": "9-Methylguanine", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2020-07-02. GROUPS: experimental. DESCRIPTION: dihydroneopterin aldolase activity. AVERAGE-MASS: 165.1527. MONOISOTOPIC-MASS: 165.065059871. UNII: 3"}, {"drug_name": "Isobutyric acid", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2020-07-02. GROUPS: experimental. DESCRIPTION: hydrolase activity. AVERAGE-MASS: 88.1051. MONOISOTOPIC-MASS: 88.0524295. UNII: 8LL210O1U0. CAS-NUMBE"}, {"drug_name": "Phosphorylisopropane", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2020-06-12. GROUPS: experimental. DESCRIPTION: extracellular matrix. AVERAGE-MASS: 140.0749. MONOISOTOPIC-MASS: 140.023845288. UNII: 7H0HVR60ZW. STA"}], "num_chunks": 5}}
{"drug_name": "Alteplase", "question": "When was Alteplase first approved by the FDA and for what initial purpose?", "ground_truth_answer": "Alteplase was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).", "ground_truth_context": {"Name": "Alteplase", "Description": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells. It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).", "MoA": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) that converts plasminogen to plasmin in a fibrin-dependent process. In the presence of fibrin clots, alteplase binds to fibrin and cleaves the arginine-valine bond at positions 560 and 561 of plasminogen, converting it into its active form, plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus and promotes clot dissolution. Alteplase initiates local fibrinolysis with limited systemic proteolysis.", "Targets": "Plasminogen, Fibrin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Alteplase was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).", "rag_full_output": {"answer": "Alteplase was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).", "drug_extracted": "Alteplase", "chunks_used": [{"drug_name": "Alteplase", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent.[L4"}, {"drug_name": "Alteplase", "type": "general", "preview": ". This was followed by 50 mg of alteplase in 1 h and 30 mg in 1.5 h, resulting in steady-state plasma levels of 2210 ng/ml and 930 ng/ml, respectively.[A252285]. HALF-LIFE: Alteplase has an initial ha"}], "num_chunks": 2}}
{"drug_name": "Alteplase", "question": "What is the role of plasmin after it is formed by Alteplase?", "ground_truth_answer": "Plasmin degrades the fibrin matrix of the thrombus and promotes clot dissolution.", "ground_truth_context": {"Name": "Alteplase", "Description": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells. It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).", "MoA": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) that converts plasminogen to plasmin in a fibrin-dependent process. In the presence of fibrin clots, alteplase binds to fibrin and cleaves the arginine-valine bond at positions 560 and 561 of plasminogen, converting it into its active form, plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus and promotes clot dissolution. Alteplase initiates local fibrinolysis with limited systemic proteolysis.", "Targets": "Plasminogen, Fibrin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as [fibrinolysin] - as part of the fibrinolytic pathway that breaks down fibrin blood clots.", "rag_full_output": {"answer": "Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as [fibrinolysin] - as part of the fibrinolytic pathway that breaks down fibrin blood clots.", "drug_extracted": "Plasmin", "chunks_used": [{"drug_name": "Plasminogen", "type": "general", "preview": "TYPE: biotech. CREATED: 2021-06-17. UPDATED: 2021-06-22. GROUPS: approved. DESCRIPTION: Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as [fibrinolysin] - a"}, {"drug_name": "Plasminogen", "type": "general", "preview": ". CAS-NUMBER: 9001-91-6. STATE: solid. INDICATION: Plasma-derived human plasminogen, marketed under the brand name Ryplazim, is indicated for the treatment of patients with plasminogen deficiency type"}, {"drug_name": "Plasminogen", "type": "general", "preview": ". Interestingly, this disease does not increase the risk of clotting, but rather results in the formation of lignous pseudomembranous lesions on the mucous membranes of the body.[L34625] Lesions range"}, {"drug_name": "Plasminogen", "type": "general", "preview": ". PHARMACODYNAMICS: The intravenous administration of plasminogen temporarily increases levels of plasminogen in the blood, allowing for the reduction or resolution of the lignous lesions associated w"}], "num_chunks": 4}}
{"drug_name": "Sermorelin", "question": "What is Sermorelin acetate?", "ground_truth_answer": "Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.", "ground_truth_context": {"Name": "Sermorelin", "Description": "Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.", "MoA": "Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.", "Targets": "Growth hormone releasing hormone receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.", "rag_full_output": {"answer": "Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.", "drug_extracted": "sermorlin acetate", "chunks_used": [{"drug_name": "Sermorelin", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved withdrawn. DESCRIPTION: Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 )"}, {"drug_name": "Sertraline", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibi"}, {"drug_name": "Tesamorelin", "type": "general", "preview": "TYPE: biotech. CREATED: 2013-05-01. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormo"}, {"drug_name": "Enalaprilat", "type": "general", "preview": "TYPE: small molecule. CREATED: 2015-11-30. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Enalaprilat is the active metabolite of the orally available pro-drug, [enalapril]. Used in the treatment"}, {"drug_name": "Fosinopril", "type": "general", "preview": ". CAS-NUMBER: 98048-97-6. STATE: solid. DRUG-INTERACTIONS: Warfarin, Bumetanide, Icatibant, Ramipril, Dersalazine, Cefditoren, Harmaline, Meloxicam, Benzthiazide, Choline salicylate (...and 1167 more)"}], "num_chunks": 5}}
{"drug_name": "Sermorelin", "question": "What is the mechanism of action of Sermorelin?", "ground_truth_answer": "Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.", "ground_truth_context": {"Name": "Sermorelin", "Description": "Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.", "MoA": "Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.", "Targets": "Growth hormone releasing hormone receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Sermorelin is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.", "rag_full_output": {"answer": "Sermorelin is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.", "drug_extracted": "sermorelin", "chunks_used": [{"drug_name": "Sermorelin", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved withdrawn. DESCRIPTION: Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 )"}], "num_chunks": 1}}
{"drug_name": "Sermorelin", "question": "What receptor does Sermorelin bind to?", "ground_truth_answer": "Sermorelin binds to the growth hormone releasing hormone receptor.", "ground_truth_context": {"Name": "Sermorelin", "Description": "Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.", "MoA": "Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.", "Targets": "Growth hormone releasing hormone receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Sermorelin binds to the growth hormone releasing hormone receptor.", "rag_full_output": {"answer": "Sermorelin binds to the growth hormone releasing hormone receptor.", "drug_extracted": "Sermorelin", "chunks_used": [{"drug_name": "Sermorelin", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved withdrawn. DESCRIPTION: Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 )"}], "num_chunks": 1}}
{"drug_name": "Sermorelin", "question": "How does Sermorelin affect growth hormone secretion?", "ground_truth_answer": "Sermorelin mimics native GRF in its ability to stimulate growth hormone secretion.", "ground_truth_context": {"Name": "Sermorelin", "Description": "Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.", "MoA": "Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.", "Targets": "Growth hormone releasing hormone receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Sermorelin is used in the treatment of children with growth hormone deficiency or growth failure.", "rag_full_output": {"answer": "Sermorelin is used in the treatment of children with growth hormone deficiency or growth failure.", "drug_extracted": "Sermorelin", "chunks_used": [{"drug_name": "Sermorelin", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved withdrawn. DESCRIPTION: Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 )"}, {"drug_name": "Sermorelin", "type": "general", "preview": ". ATC-CODES: OTHER DIAGNOSTIC AGENTS VARIOUS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES DIAGNOSTIC AGENTS Tests for pituitary function ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES Somatropin "}], "num_chunks": 2}}
{"drug_name": "Sermorelin", "question": "What type of molecule is Sermorelin acetate?", "ground_truth_answer": "Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide.", "ground_truth_context": {"Name": "Sermorelin", "Description": "Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.", "MoA": "Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.", "Targets": "Growth hormone releasing hormone receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Sermorelin acetate is a biotech.", "rag_full_output": {"answer": "Sermorelin acetate is a biotech.", "drug_extracted": "sermorelin acetate", "chunks_used": [{"drug_name": "Sermorelin", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved withdrawn. DESCRIPTION: Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 )"}, {"drug_name": "Methacholine", "type": "general", "preview": "TYPE: small molecule. CREATED: 2010-05-16. UPDATED: 2023-01-03. GROUPS: approved investigational"}, {"drug_name": "Edaravone", "type": "general", "preview": "TYPE: small molecule. CREATED: 2016-10-20. UPDATED: 2023-01-03. GROUPS: approved investigational"}, {"drug_name": "Lurbinectedin", "type": "general", "preview": "TYPE: small molecule. CREATED: 2016-10-20. UPDATED: 2023-01-03. GROUPS: approved investigational"}, {"drug_name": "Bortezomib", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational"}], "num_chunks": 5}}
{"drug_name": "Interferon alfa-n1", "question": "What is Interferon alfa-n1?", "ground_truth_answer": "Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated.", "ground_truth_context": {"Name": "Interferon alfa-n1", "Description": "Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, Stat2", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated.", "rag_full_output": {"answer": "Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated.", "drug_extracted": "Interferon alfa-n1", "chunks_used": [{"drug_name": "Interferon alfa-n1", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, a"}], "num_chunks": 1}}
{"drug_name": "Interferon alfa-n1", "question": "How does Interferon alfa-n1 differ from recombinant alpha interferons?", "ground_truth_answer": "Interferon alfa-n1 differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.", "ground_truth_context": {"Name": "Interferon alfa-n1", "Description": "Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, Stat2", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated.", "rag_full_output": {"answer": "Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated.", "drug_extracted": "Interferon alfa-n1", "chunks_used": [{"drug_name": "Interferon alfa-n1", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, a"}], "num_chunks": 1}}
{"drug_name": "Interferon alfa-n1", "question": "What is the mechanism of action of Interferon alfa-n1?", "ground_truth_answer": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins.", "ground_truth_context": {"Name": "Interferon alfa-n1", "Description": "Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, Stat2", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Interferon alfa-n1 binds less stably to type I interferon receptors than interferon beta.", "rag_full_output": {"answer": "Interferon alfa-n1 binds less stably to type I interferon receptors than interferon beta.", "drug_extracted": "Interferon alfa-n1", "chunks_used": [{"drug_name": "Interferon alfa-n1", "type": "general", "preview": ". These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimeriz"}], "num_chunks": 1}}
{"drug_name": "Interferon alfa-n1", "question": "What are the primary targets of Interferon alfa-n1's binding action?", "ground_truth_answer": "Interferon alfa-n1 primarily targets type I interferon receptors (IFNAR1 and IFNAR2c).", "ground_truth_context": {"Name": "Interferon alfa-n1", "Description": "Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, Stat2", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Interferon alfa-n1 primarily targets type I interferon receptors (IFNAR1 and IFNAR2c).", "rag_full_output": {"answer": "Interferon alfa-n1 binds to type I interferon receptors.", "drug_extracted": "Interferon alfa-n1", "chunks_used": [{"drug_name": "Interferon alfa-n1", "type": "general", "preview": ". These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimeriz"}], "num_chunks": 1}}
{"drug_name": "Interferon alfa-n1", "question": "Which kinases are activated when type I interferon receptors dimerize after binding with Interferon alfa-n1?", "ground_truth_answer": "Two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2) are activated.", "ground_truth_context": {"Name": "Interferon alfa-n1", "Description": "Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, Stat2", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2) are activated.", "rag_full_output": {"answer": "Interferon alpha binds less stably to type I interferon receptors than interferon beta.", "drug_extracted": "Interferon alfa-n1", "chunks_used": [{"drug_name": "Interferon alfa-n1", "type": "general", "preview": ". These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimeriz"}], "num_chunks": 1}}
{"drug_name": "Darbepoetin alfa", "question": "What is Darbepoetin alfa?", "ground_truth_answer": "Darbepoetin alfa is human erythropoietin with 2 amino acid substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD), produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.", "ground_truth_context": {"Name": "Darbepoetin alfa", "Description": "Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.", "MoA": "Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.", "Targets": "Erythropoietin receptor, progenitor stem cells", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Darbepoetin alfa is a human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD).", "rag_full_output": {"answer": "Darbepoetin alfa is a human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD).", "drug_extracted": "Darbepoetin alfa", "chunks_used": [{"drug_name": "Darbepoetin alfa", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 r"}], "num_chunks": 1}}
{"drug_name": "Darbepoetin alfa", "question": "How does Darbepoetin alfa stimulate erythropoiesis?", "ground_truth_answer": "Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin, interacting with progenitor stem cells to increase red cell production.", "ground_truth_context": {"Name": "Darbepoetin alfa", "Description": "Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.", "MoA": "Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.", "Targets": "Erythropoietin receptor, progenitor stem cells", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin.", "rag_full_output": {"answer": "Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin.", "drug_extracted": "Darbepoetin alfa", "chunks_used": [{"drug_name": "Darbepoetin alfa", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 r"}, {"drug_name": "Darbepoetin alfa", "type": "general", "preview": ". Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transd"}], "num_chunks": 2}}
{"drug_name": "Darbepoetin alfa", "question": "What occurs when erythropoietin binds to its receptor?", "ground_truth_answer": "Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol.", "ground_truth_context": {"Name": "Darbepoetin alfa", "Description": "Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.", "MoA": "Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.", "Targets": "Erythropoietin receptor, progenitor stem cells", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol.", "rag_full_output": {"answer": "Erythropoietin and epoetin alfa are involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.", "drug_extracted": "erythropoietin", "chunks_used": [{"drug_name": "Erythropoietin", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000654. DRUG-INTERACTIONS: Epothilone D, 3,4-Dihydroxybenzoic Acid, Azacitidine, Naquotinib, Maxacalcitol, Blinatumomab, Ramipril, Suramin, Ixazomib, Irofulven (...and 471"}, {"drug_name": "Erythropoietin", "type": "general", "preview": ". Via JAK2-mediated tyrosine phosphorylation, erythropoietin and epoetin alfa also activates other intracellular proteins involved in erythroid cell proliferation and survival, such as Shc , phosphati"}, {"drug_name": "Erythropoietin", "type": "general", "preview": ". ROUTE-OF-ELIMINATION: Erythropoietin and epoetin alfa are cleared via uptake and degradation via the EPO-R-expressing cells, and may also involve other cellular pathways in the interstitium, probabl"}], "num_chunks": 3}}
{"drug_name": "Darbepoetin alfa", "question": "What is the function of activated STAT proteins in the mechanism of action?", "ground_truth_answer": "Activated STAT proteins are translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.", "ground_truth_context": {"Name": "Darbepoetin alfa", "Description": "Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.", "MoA": "Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.", "Targets": "Erythropoietin receptor, progenitor stem cells", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Atorvastatin also reduces Very-Low-Density Lipoprotein-Cholesterol (VLDL-C), serum triglycerides (TG) and Intermediate Density Lipoproteins (IDL), as well as the number of apolipoprotein B (apo B) containing particles, but increases High-Density Lipoprotein Cholesterol (HDL-C).", "rag_full_output": {"answer": "Atorvastatin also reduces Very-Low-Density Lipoprotein-Cholesterol (VLDL-C), serum triglycerides (TG) and Intermediate Density Lipoproteins (IDL), as well as the number of apolipoprotein B (apo B) containing particles, but increases High-Density Lipoprotein Cholesterol (HDL-C).", "drug_extracted": "STAT", "chunks_used": [{"drug_name": "Atorvastatin", "type": "general", "preview": ". Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke,"}, {"drug_name": "Simvastatin", "type": "general", "preview": ". Statins have also been found to bind allosterically to β2 integrin function-associated antigen-1 (LFA-1), which plays an important role in leukocyte trafficking and in T cell activation.[A181559]. A"}, {"drug_name": "Rosuvastatin", "type": "general", "preview": ". MECHANISM-OF-ACTION: Rosuvastatin is a statin medication and a competitive inhibitor of the enzyme HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, which catalyzes the conversion of HMG-Co"}, {"drug_name": "Atorvastatin", "type": "general", "preview": ". Atorvastatin also reduces Very-Low-Density Lipoprotein-Cholesterol (VLDL-C), serum triglycerides (TG) and Intermediate Density Lipoproteins (IDL), as well as the number of apolipoprotein B (apo B) c"}], "num_chunks": 4}}
{"drug_name": "Darbepoetin alfa", "question": "What is the molecular weight of Darbepoetin alfa?", "ground_truth_answer": "The molecular weight of Darbepoetin alfa is 37 kD.", "ground_truth_context": {"Name": "Darbepoetin alfa", "Description": "Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.", "MoA": "Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.", "Targets": "Erythropoietin receptor, progenitor stem cells", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "The molecular weight of Darbepoetin alfa is 371.393.", "rag_full_output": {"answer": "The molecular weight of Darbepoetin alfa is 371.393.", "drug_extracted": "Darbepoetin alfa", "chunks_used": [{"drug_name": "D-Lysine", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2020-06-12. GROUPS: experimental. DESCRIPTION: An essential amino acid. It is often added to animal feed. [PubChem]. AVERAGE-MASS: 146.1876. MONOISO"}, {"drug_name": "Albutrepenonacog alfa", "type": "general", "preview": "TYPE: biotech. CREATED: 2017-09-07. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Albutrepenonacog alfa (rIX-RFP) is a recombinant fusion protein that links a recombinant coagulation factor IX ("}, {"drug_name": "Eprinomectin", "type": "general", "preview": "TYPE: small molecule. CREATED: 2016-02-25. UPDATED: 2021-02-21. GROUPS: vet_approved. DESCRIPTION: cytoplasm. AVERAGE-MASS: 900.116. MONOISOTOPIC-MASS: 899.503106035. UNII: 75KP30FD8O. CAS-NUMBER: 123"}, {"drug_name": "Cephalosporin analog", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2020-06-12. GROUPS: experimental. DESCRIPTION: extracellular region. AVERAGE-MASS: 750.773. MONOISOTOPIC-MASS: 750.25305615. STATE: solid. TARGETS: "}, {"drug_name": "Darodipine", "type": "general", "preview": "TYPE: small molecule. CREATED: 2015-10-23. UPDATED: 2021-02-21. GROUPS: experimental. DESCRIPTION: Darodipine is a calcium channel blocker.. AVERAGE-MASS: 371.393. MONOISOTOPIC-MASS: 371.148120788. UN"}], "num_chunks": 5}}
{"drug_name": "Urokinase", "question": "What is the mechanism of action of Urokinase?", "ground_truth_answer": "Urokinase is a serine protease. It cleaves plasminogen to form the active fibrinolytic protease, plasmin.", "ground_truth_context": {"Name": "Urokinase", "Description": "Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978.", "MoA": "Urokinase is a serine protease. It cleaves plasminogen to form the active fibrinolytic protease, plasmin.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Urokinase is a serine protease that activates plasminogen to an active fibrinolytic protease.", "rag_full_output": {"answer": "Urokinase is a serine protease that activates plasminogen to an active fibrinolytic protease.", "drug_extracted": "Urokinase", "chunks_used": [{"drug_name": "Urokinase", "type": "general", "preview": ". MECHANISM-OF-ACTION: Urokinase is a serine protease.[A191928] It cleaves plasminogen to form the active fibrinolytic protease, plasmin.[A191928]. ATC-CODES: BLOOD AND BLOOD FORMING ORGANS ANTITHROMB"}, {"drug_name": "Urokinase", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational withdrawn. DESCRIPTION: Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between "}], "num_chunks": 2}}
{"drug_name": "Urokinase", "question": "When was Urokinase granted FDA approval?", "ground_truth_answer": "Urokinase was granted FDA approval on 16 January 1978.", "ground_truth_context": {"Name": "Urokinase", "Description": "Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978.", "MoA": "Urokinase is a serine protease. It cleaves plasminogen to form the active fibrinolytic protease, plasmin.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Urokinase was granted FDA approval on 16 January 1978.", "rag_full_output": {"answer": "Urokinase was granted FDA approval on 16 January 1978.", "drug_extracted": "Urokinase", "chunks_used": [{"drug_name": "Urokinase", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational withdrawn. DESCRIPTION: Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between "}], "num_chunks": 1}}
{"drug_name": "Urokinase", "question": "What kind of peptide is Urokinase?", "ground_truth_answer": "Urokinase is an endogenous peptide.", "ground_truth_context": {"Name": "Urokinase", "Description": "Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978.", "MoA": "Urokinase is a serine protease. It cleaves plasminogen to form the active fibrinolytic protease, plasmin.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase.", "rag_full_output": {"answer": "Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase.", "drug_extracted": "Urokinase", "chunks_used": [{"drug_name": "Urokinase", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational withdrawn. DESCRIPTION: Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between "}, {"drug_name": "Urokinase", "type": "general", "preview": ". MECHANISM-OF-ACTION: Urokinase is a serine protease.[A191928] It cleaves plasminogen to form the active fibrinolytic protease, plasmin.[A191928]. ATC-CODES: BLOOD AND BLOOD FORMING ORGANS ANTITHROMB"}], "num_chunks": 2}}
{"drug_name": "Urokinase", "question": "How are the two chains of Urokinase connected after cleavage?", "ground_truth_answer": "Urokinase remains connected between these 2 chains by a sulfhydryl bond.", "ground_truth_context": {"Name": "Urokinase", "Description": "Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978.", "MoA": "Urokinase is a serine protease. It cleaves plasminogen to form the active fibrinolytic protease, plasmin.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Urokinase is a serine protease that activates plasminogen to an active fibrinolytic protease.", "rag_full_output": {"answer": "Urokinase is a serine protease that activates plasminogen to an active fibrinolytic protease.", "drug_extracted": "Urokinase", "chunks_used": [{"drug_name": "Urokinase", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational withdrawn. DESCRIPTION: Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between "}, {"drug_name": "Urokinase", "type": "general", "preview": ". MECHANISM-OF-ACTION: Urokinase is a serine protease.[A191928] It cleaves plasminogen to form the active fibrinolytic protease, plasmin.[A191928]. ATC-CODES: BLOOD AND BLOOD FORMING ORGANS ANTITHROMB"}], "num_chunks": 2}}
{"drug_name": "Urokinase", "question": "What is the target of Urokinase?", "ground_truth_answer": "Urokinase targets plasminogen.", "ground_truth_context": {"Name": "Urokinase", "Description": "Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978.", "MoA": "Urokinase is a serine protease. It cleaves plasminogen to form the active fibrinolytic protease, plasmin.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Urokinase targets plasminogen.", "rag_full_output": {"answer": "Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase.", "drug_extracted": "Urokinase", "chunks_used": [{"drug_name": "Urokinase", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational withdrawn. DESCRIPTION: Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between "}], "num_chunks": 1}}
{"drug_name": "Goserelin", "question": "What is Goserelin?", "ground_truth_answer": "Goserelin is a synthetic hormone.", "ground_truth_context": {"Name": "Goserelin", "Description": "Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.", "MoA": "Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.", "Targets": "Pituitary gonadotropin secretion, LHRH, LH, testosterone, estradiol", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Goserelin is a synthetic hormone.", "rag_full_output": {"answer": "Goserelin is a synthetic hormone.", "drug_extracted": "Goserelin", "chunks_used": [{"drug_name": "Goserelin", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may "}, {"drug_name": "Goserelin", "type": "general", "preview": ". INDICATION: Goserelin is indicated for: - Use in combination with flutamide for the management of locally confined carcinoma of the prostate - Palliative treatment of advanced carcinoma of the prost"}, {"drug_name": "Goserelin", "type": "general", "preview": ". In these studies, goserelin was administered as a single 250µg (aqueous solution) dose and as a single or multiple 3.6 mg depot dose by subcutaneous route.. ABSORPTION: Inactive orally, rapidly abso"}], "num_chunks": 3}}
{"drug_name": "Goserelin", "question": "How does Goserelin work in men?", "ground_truth_answer": "In men, Goserelin stops the production of the hormone testosterone, which may stimulate the growth of cancer cells.", "ground_truth_context": {"Name": "Goserelin", "Description": "Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.", "MoA": "Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.", "Targets": "Pituitary gonadotropin secretion, LHRH, LH, testosterone, estradiol", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Goserelin is a synthetic hormone.", "rag_full_output": {"answer": "Goserelin is a synthetic hormone.", "drug_extracted": "Goserelin", "chunks_used": [{"drug_name": "Goserelin", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may "}, {"drug_name": "Goserelin", "type": "general", "preview": ". INDICATION: Goserelin is indicated for: - Use in combination with flutamide for the management of locally confined carcinoma of the prostate - Palliative treatment of advanced carcinoma of the prost"}], "num_chunks": 2}}
{"drug_name": "Goserelin", "question": "What is the mechanism of action of Goserelin?", "ground_truth_answer": "Goserelin is a synthetic decapeptide analogue of LHRH that acts as a potent inhibitor of pituitary gonadotropin secretion, resulting in sustained suppression of LH and serum testosterone levels.", "ground_truth_context": {"Name": "Goserelin", "Description": "Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.", "MoA": "Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.", "Targets": "Pituitary gonadotropin secretion, LHRH, LH, testosterone, estradiol", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Goserelin is a synthetic hormone.", "rag_full_output": {"answer": "Goserelin is a synthetic hormone.", "drug_extracted": "goserelin", "chunks_used": [{"drug_name": "Goserelin", "type": "general", "preview": ". INDICATION: Goserelin is indicated for: - Use in combination with flutamide for the management of locally confined carcinoma of the prostate - Palliative treatment of advanced carcinoma of the prost"}, {"drug_name": "Goserelin", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may "}, {"drug_name": "Goserelin", "type": "general", "preview": ". In these studies, goserelin was administered as a single 250µg (aqueous solution) dose and as a single or multiple 3.6 mg depot dose by subcutaneous route.. ABSORPTION: Inactive orally, rapidly abso"}], "num_chunks": 3}}
{"drug_name": "Goserelin", "question": "What happens to hormone levels when Goserelin medication is stopped?", "ground_truth_answer": "When the medication is stopped, hormone levels return to normal.", "ground_truth_context": {"Name": "Goserelin", "Description": "Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.", "MoA": "Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.", "Targets": "Pituitary gonadotropin secretion, LHRH, LH, testosterone, estradiol", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "When the medication is stopped, hormone levels return to normal.", "rag_full_output": {"answer": "When the medication is stopped, hormone levels return to normal.", "drug_extracted": "Goserelin", "chunks_used": [{"drug_name": "Goserelin", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may "}, {"drug_name": "Goserelin", "type": "general", "preview": ". INDICATION: Goserelin is indicated for: - Use in combination with flutamide for the management of locally confined carcinoma of the prostate - Palliative treatment of advanced carcinoma of the prost"}], "num_chunks": 2}}
{"drug_name": "Goserelin", "question": "How does Goserelin affect hormone levels in women?", "ground_truth_answer": "In women, goserelin decreases the production of the hormone estradiol to levels similar to a postmenopausal state.", "ground_truth_context": {"Name": "Goserelin", "Description": "Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.", "MoA": "Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.", "Targets": "Pituitary gonadotropin secretion, LHRH, LH, testosterone, estradiol", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "In women, goserelin decreases the production of the hormone estradiol to levels similar to a postmenopausal state.", "rag_full_output": {"answer": "Goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state.", "drug_extracted": "Goserelin", "chunks_used": [{"drug_name": "Goserelin", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may "}, {"drug_name": "Goserelin", "type": "general", "preview": ". INDICATION: Goserelin is indicated for: - Use in combination with flutamide for the management of locally confined carcinoma of the prostate - Palliative treatment of advanced carcinoma of the prost"}], "num_chunks": 2}}
{"drug_name": "Reteplase", "question": "What is Reteplase?", "ground_truth_answer": "Reteplase is a human tissue plasminogen activator, purified, glycosylated, with 355 residues purified from CHO cells, considered a \"third-generation\" thrombolytic agent.", "ground_truth_context": {"Name": "Reteplase", "Description": "Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a \"third-generation\" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).", "MoA": "Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells.", "rag_full_output": {"answer": "Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells.", "drug_extracted": "Reteplase", "chunks_used": [{"drug_name": "Reteplase", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells"}], "num_chunks": 1}}
{"drug_name": "Reteplase", "question": "What is the mechanism of action of Reteplase?", "ground_truth_answer": "Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain, then its protease domain cleaves the Arg/Val bond in plasminogen to form plasmin, which degrades the fibrin matrix of the thrombus.", "ground_truth_context": {"Name": "Reteplase", "Description": "Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a \"third-generation\" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).", "MoA": "Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain, then its protease domain cleaves the Arg/Val bond in plasminogen to form plasmin, which degrades the fibrin matrix of the thrombus.", "rag_full_output": {"answer": "Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain.", "drug_extracted": "Reteplase", "chunks_used": [{"drug_name": "Reteplase", "type": "general", "preview": ". CAS-NUMBER: 133652-38-7. STATE: liquid. DRUG-INTERACTIONS: Indomethacin, Indalpine, Warfarin, Azacitidine, Medrogestone, Esterified estrogens, Icatibant, Trazodone, Blinatumomab, Zaltoprofen (...and"}, {"drug_name": "Reteplase", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells"}], "num_chunks": 2}}
{"drug_name": "Reteplase", "question": "Which specific domains of human tPA are retained in Reteplase?", "ground_truth_answer": "Reteplase retains the activity-related kringle-2 and serine protease domains of human tPA.", "ground_truth_context": {"Name": "Reteplase", "Description": "Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a \"third-generation\" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).", "MoA": "Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Reteplase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA.", "rag_full_output": {"answer": "Reteplase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA.", "drug_extracted": "Reteplase", "chunks_used": [{"drug_name": "Reteplase", "type": "general", "preview": ". CAS-NUMBER: 133652-38-7. STATE: liquid. DRUG-INTERACTIONS: Indomethacin, Indalpine, Warfarin, Azacitidine, Medrogestone, Esterified estrogens, Icatibant, Trazodone, Blinatumomab, Zaltoprofen (...and"}, {"drug_name": "Reteplase", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells"}], "num_chunks": 2}}
{"drug_name": "Reteplase", "question": "What domains are deleted from Reteplase compared to native human tPA?", "ground_truth_answer": "Three domains are deleted from retavase: kringle-1, finger, and epidermal growth factor (EGF).", "ground_truth_context": {"Name": "Reteplase", "Description": "Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a \"third-generation\" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).", "MoA": "Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Reteplase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA.", "rag_full_output": {"answer": "Reteplase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA.", "drug_extracted": "Reteplase", "chunks_used": [{"drug_name": "Reteplase", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells"}], "num_chunks": 1}}
{"drug_name": "Reteplase", "question": "What molecule does Reteplase cleave to initiate its thrombolytic action?", "ground_truth_answer": "Reteplase cleaves the Arg/Val bond in plasminogen to form plasmin.", "ground_truth_context": {"Name": "Reteplase", "Description": "Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a \"third-generation\" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).", "MoA": "Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Reteplase cleaves the Arg/Val bond in plasminogen to form plasmin.", "rag_full_output": {"answer": "Reteplase cleaves the Arg/Val bond in plasminogen to form plasmin.", "drug_extracted": "Reteplase", "chunks_used": [{"drug_name": "Reteplase", "type": "general", "preview": ". CAS-NUMBER: 133652-38-7. STATE: liquid. DRUG-INTERACTIONS: Indomethacin, Indalpine, Warfarin, Azacitidine, Medrogestone, Esterified estrogens, Icatibant, Trazodone, Blinatumomab, Zaltoprofen (...and"}], "num_chunks": 1}}
{"drug_name": "Erythropoietin", "question": "What is Erythropoietin (EPO)?", "ground_truth_answer": "Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells.", "ground_truth_context": {"Name": "Erythropoietin (EPO)", "Description": "Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein produced in cell culture using recombinant DNA technology and is used for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures. It has a molecular weight of approximately 30,400 daltons. Epoetin alfa biosimilars, such as Retacrit (epoetin alfa-epbx or epoetin zeta), also exist.", "MoA": "Erythropoietin or exogenous epoetin alfa binds to the erythropoietin receptor (EPO-R) and activates intracellular signal transduction pathways. Upon binding to EPO-R, a conformational change brings EPO-R-associated Janus family tyrosine protein kinase 2 (JAK2) molecules into close proximity, leading to their phosphorylation. JAK2 then phosphorylates tyrosine residues in the cytoplasmic domain of the EPO-R, which serve as docking sites for Src homology 2-domain-containing intracellular signaling proteins, including STAT5. Phosphorylated STAT5 dissociates from the EPO-R, dimerizes, and translocates to the nucleus to activate target genes involved in cell division or differentiation, including the apoptosis inhibitor Bcl-x. Erythropoietin and epoetin alfa also activate Shc, phosphatidylinositol 3-kinase (PI3K), and phospholipase C-γ1 via JAK2-mediated tyrosine phosphorylation.", "Targets": "Erythropoietin receptor (EPO-R), Janus family tyrosine protein kinase 2 (JAK2), STAT5, Bcl-x, Shc, phosphatidylinositol 3-kinase (PI3K), phospholipase C-γ1", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells.", "rag_full_output": {"answer": "Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells.", "drug_extracted": "erythropoietin", "chunks_used": [{"drug_name": "Erythropoietin", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cell"}, {"drug_name": "Erythropoietin", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000654. DRUG-INTERACTIONS: Epothilone D, 3,4-Dihydroxybenzoic Acid, Azacitidine, Naquotinib, Maxacalcitol, Blinatumomab, Ramipril, Suramin, Ixazomib, Irofulven (...and 471"}, {"drug_name": "Erythropoietin", "type": "general", "preview": ". Via JAK2-mediated tyrosine phosphorylation, erythropoietin and epoetin alfa also activates other intracellular proteins involved in erythroid cell proliferation and survival, such as Shc , phosphati"}], "num_chunks": 3}}
{"drug_name": "Erythropoietin", "question": "What is the primary mechanism of action of Erythropoietin or epoetin alfa?", "ground_truth_answer": "Erythropoietin or exogenous epoetin alfa binds to the erythropoietin receptor (EPO-R) and activates intracellular signal transduction pathways, primarily involving JAK2 and STAT5.", "ground_truth_context": {"Name": "Erythropoietin (EPO)", "Description": "Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein produced in cell culture using recombinant DNA technology and is used for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures. It has a molecular weight of approximately 30,400 daltons. Epoetin alfa biosimilars, such as Retacrit (epoetin alfa-epbx or epoetin zeta), also exist.", "MoA": "Erythropoietin or exogenous epoetin alfa binds to the erythropoietin receptor (EPO-R) and activates intracellular signal transduction pathways. Upon binding to EPO-R, a conformational change brings EPO-R-associated Janus family tyrosine protein kinase 2 (JAK2) molecules into close proximity, leading to their phosphorylation. JAK2 then phosphorylates tyrosine residues in the cytoplasmic domain of the EPO-R, which serve as docking sites for Src homology 2-domain-containing intracellular signaling proteins, including STAT5. Phosphorylated STAT5 dissociates from the EPO-R, dimerizes, and translocates to the nucleus to activate target genes involved in cell division or differentiation, including the apoptosis inhibitor Bcl-x. Erythropoietin and epoetin alfa also activate Shc, phosphatidylinositol 3-kinase (PI3K), and phospholipase C-γ1 via JAK2-mediated tyrosine phosphorylation.", "Targets": "Erythropoietin receptor (EPO-R), Janus family tyrosine protein kinase 2 (JAK2), STAT5, Bcl-x, Shc, phosphatidylinositol 3-kinase (PI3K), phospholipase C-γ1", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Erythropoietin or exogenous epoetin alfa binds to the erythropoietin receptor (EPO-R) and activates intracellular signal transduction pathways.", "rag_full_output": {"answer": "Erythropoietin or exogenous epoetin alfa binds to the erythropoietin receptor (EPO-R) and activates intracellular signal transduction pathways.", "drug_extracted": "erythropoietin", "chunks_used": [{"drug_name": "Erythropoietin", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cell"}, {"drug_name": "Erythropoietin", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000654. DRUG-INTERACTIONS: Epothilone D, 3,4-Dihydroxybenzoic Acid, Azacitidine, Naquotinib, Maxacalcitol, Blinatumomab, Ramipril, Suramin, Ixazomib, Irofulven (...and 471"}, {"drug_name": "Erythropoietin", "type": "general", "preview": ". Epoetin alfa serves to restore erythropoietin deficiency in pathological and other clinical conditions where normal production of erythropoietin is impaired or compromised. In anemic patients with c"}, {"drug_name": "Erythropoietin", "type": "general", "preview": ". Via JAK2-mediated tyrosine phosphorylation, erythropoietin and epoetin alfa also activates other intracellular proteins involved in erythroid cell proliferation and survival, such as Shc , phosphati"}, {"drug_name": "Erythropoietin", "type": "general", "preview": ". ROUTE-OF-ELIMINATION: Erythropoietin and epoetin alfa are cleared via uptake and degradation via the EPO-R-expressing cells, and may also involve other cellular pathways in the interstitium, probabl"}], "num_chunks": 5}}
{"drug_name": "Erythropoietin", "question": "What is the molecular weight of Epoetin alfa?", "ground_truth_answer": "Epoetin alfa has a molecular weight of approximately 30,400 daltons.", "ground_truth_context": {"Name": "Erythropoietin (EPO)", "Description": "Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein produced in cell culture using recombinant DNA technology and is used for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures. It has a molecular weight of approximately 30,400 daltons. Epoetin alfa biosimilars, such as Retacrit (epoetin alfa-epbx or epoetin zeta), also exist.", "MoA": "Erythropoietin or exogenous epoetin alfa binds to the erythropoietin receptor (EPO-R) and activates intracellular signal transduction pathways. Upon binding to EPO-R, a conformational change brings EPO-R-associated Janus family tyrosine protein kinase 2 (JAK2) molecules into close proximity, leading to their phosphorylation. JAK2 then phosphorylates tyrosine residues in the cytoplasmic domain of the EPO-R, which serve as docking sites for Src homology 2-domain-containing intracellular signaling proteins, including STAT5. Phosphorylated STAT5 dissociates from the EPO-R, dimerizes, and translocates to the nucleus to activate target genes involved in cell division or differentiation, including the apoptosis inhibitor Bcl-x. Erythropoietin and epoetin alfa also activate Shc, phosphatidylinositol 3-kinase (PI3K), and phospholipase C-γ1 via JAK2-mediated tyrosine phosphorylation.", "Targets": "Erythropoietin receptor (EPO-R), Janus family tyrosine protein kinase 2 (JAK2), STAT5, Bcl-x, Shc, phosphatidylinositol 3-kinase (PI3K), phospholipase C-γ1", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Epoetin alfa has a molecular weight of approximately 30,400 daltons.", "rag_full_output": {"answer": "The molecular weight of Epoetin alfa is approximately 30,400 daltons.", "drug_extracted": "Epoetin alfa", "chunks_used": [{"drug_name": "Erythropoietin", "type": "general", "preview": ". It has a molecular weight of approximately 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced. The product contains the identical amino ac"}, {"drug_name": "Erythropoietin", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cell"}, {"drug_name": "Amdoxovir", "type": "general", "preview": "TYPE: small molecule. CREATED: 2008-03-19. UPDATED: 2022-06-28. GROUPS: investigational. DESCRIPTION: identical protein binding. AVERAGE-MASS: 252.234. MONOISOTOPIC-MASS: 252.09708827. UNII: 54I81H0M9"}, {"drug_name": "Omidenepag isopropyl", "type": "general", "preview": ". The protein binding of its active metabolite, omidenepag, is 97.8%.[L43508]"}, {"drug_name": "Cephalosporin analog", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2020-06-12. GROUPS: experimental. DESCRIPTION: extracellular region. AVERAGE-MASS: 750.773. MONOISOTOPIC-MASS: 750.25305615. STATE: solid. TARGETS: "}], "num_chunks": 5}}
{"drug_name": "Erythropoietin", "question": "What are the specific clinical conditions for which epoetin alfa is indicated?", "ground_truth_answer": "Epoetin alfa is indicated for the treatment of anemia due to Chronic Kidney Disease, anemia due to zidovudine in patients with HIV-infection, anemia due to the effects of concomitant myelosuppressive chemotherapy, and for the reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery.", "ground_truth_context": {"Name": "Erythropoietin (EPO)", "Description": "Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein produced in cell culture using recombinant DNA technology and is used for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures. It has a molecular weight of approximately 30,400 daltons. Epoetin alfa biosimilars, such as Retacrit (epoetin alfa-epbx or epoetin zeta), also exist.", "MoA": "Erythropoietin or exogenous epoetin alfa binds to the erythropoietin receptor (EPO-R) and activates intracellular signal transduction pathways. Upon binding to EPO-R, a conformational change brings EPO-R-associated Janus family tyrosine protein kinase 2 (JAK2) molecules into close proximity, leading to their phosphorylation. JAK2 then phosphorylates tyrosine residues in the cytoplasmic domain of the EPO-R, which serve as docking sites for Src homology 2-domain-containing intracellular signaling proteins, including STAT5. Phosphorylated STAT5 dissociates from the EPO-R, dimerizes, and translocates to the nucleus to activate target genes involved in cell division or differentiation, including the apoptosis inhibitor Bcl-x. Erythropoietin and epoetin alfa also activate Shc, phosphatidylinositol 3-kinase (PI3K), and phospholipase C-γ1 via JAK2-mediated tyrosine phosphorylation.", "Targets": "Erythropoietin receptor (EPO-R), Janus family tyrosine protein kinase 2 (JAK2), STAT5, Bcl-x, Shc, phosphatidylinositol 3-kinase (PI3K), phospholipase C-γ1", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Epoetin alfa is indicated in adult and paediatric patients for the: - treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis. - treatment of anemia due to zidovudine in patients with HIV-infection. - treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. - reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery.", "rag_full_output": {"answer": "Epoetin alfa is indicated in adult and paediatric patients for the: - treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis. - treatment of anemia due to zidovudine in patients with HIV-infection. - treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. - reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery.", "drug_extracted": "epoetin alfa", "chunks_used": [{"drug_name": "Erythropoietin", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cell"}, {"drug_name": "Erythropoietin", "type": "general", "preview": ". Epoetin alfa serves to restore erythropoietin deficiency in pathological and other clinical conditions where normal production of erythropoietin is impaired or compromised. In anemic patients with c"}, {"drug_name": "Erythropoietin", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000654. DRUG-INTERACTIONS: Epothilone D, 3,4-Dihydroxybenzoic Acid, Azacitidine, Naquotinib, Maxacalcitol, Blinatumomab, Ramipril, Suramin, Ixazomib, Irofulven (...and 471"}, {"drug_name": "Erythropoietin", "type": "general", "preview": ". ROUTE-OF-ELIMINATION: Erythropoietin and epoetin alfa are cleared via uptake and degradation via the EPO-R-expressing cells, and may also involve other cellular pathways in the interstitium, probabl"}, {"drug_name": "Vadadustat", "type": "general", "preview": "TYPE: small molecule. CREATED: 2016-10-20. UPDATED: 2022-01-08. GROUPS: investigational. DESCRIPTION: One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inabi"}], "num_chunks": 5}}
{"drug_name": "Erythropoietin", "question": "Which intracellular signaling proteins are activated by erythropoietin and epoetin alfa through JAK2-mediated tyrosine phosphorylation?", "ground_truth_answer": "Erythropoietin and epoetin alfa activate Shc, phosphatidylinositol 3-kinase (PI3K), phospholipase C-γ1, and STAT5 via JAK2-mediated tyrosine phosphorylation.", "ground_truth_context": {"Name": "Erythropoietin (EPO)", "Description": "Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein produced in cell culture using recombinant DNA technology and is used for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures. It has a molecular weight of approximately 30,400 daltons. Epoetin alfa biosimilars, such as Retacrit (epoetin alfa-epbx or epoetin zeta), also exist.", "MoA": "Erythropoietin or exogenous epoetin alfa binds to the erythropoietin receptor (EPO-R) and activates intracellular signal transduction pathways. Upon binding to EPO-R, a conformational change brings EPO-R-associated Janus family tyrosine protein kinase 2 (JAK2) molecules into close proximity, leading to their phosphorylation. JAK2 then phosphorylates tyrosine residues in the cytoplasmic domain of the EPO-R, which serve as docking sites for Src homology 2-domain-containing intracellular signaling proteins, including STAT5. Phosphorylated STAT5 dissociates from the EPO-R, dimerizes, and translocates to the nucleus to activate target genes involved in cell division or differentiation, including the apoptosis inhibitor Bcl-x. Erythropoietin and epoetin alfa also activate Shc, phosphatidylinositol 3-kinase (PI3K), and phospholipase C-γ1 via JAK2-mediated tyrosine phosphorylation.", "Targets": "Erythropoietin receptor (EPO-R), Janus family tyrosine protein kinase 2 (JAK2), STAT5, Bcl-x, Shc, phosphatidylinositol 3-kinase (PI3K), phospholipase C-γ1", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Erythropoietin and epoetin alfa activate other intracellular proteins involved in erythroid cell proliferation and survival, such as Shc , phosphatidylinositol 3-kinase (PI3K), and phospholipase C-γ1 [A33079].", "rag_full_output": {"answer": "Erythropoietin and epoetin alfa activate other intracellular proteins involved in erythroid cell proliferation and survival, such as Shc , phosphatidylinositol 3-kinase (PI3K), and phospholipase C-γ1 [A33079].", "drug_extracted": "erythropoietin", "chunks_used": [{"drug_name": "Erythropoietin", "type": "general", "preview": ". Via JAK2-mediated tyrosine phosphorylation, erythropoietin and epoetin alfa also activates other intracellular proteins involved in erythroid cell proliferation and survival, such as Shc , phosphati"}, {"drug_name": "Erythropoietin", "type": "general", "preview": ". Upon binding to EPO-R on the surface of erythroid progenitor cells, a conformational change is induced which brings EPO-R-associated Janus family tyrosine protein kinase 2 (JAK2) molecules into clos"}, {"drug_name": "Erythropoietin", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000654. DRUG-INTERACTIONS: Epothilone D, 3,4-Dihydroxybenzoic Acid, Azacitidine, Naquotinib, Maxacalcitol, Blinatumomab, Ramipril, Suramin, Ixazomib, Irofulven (...and 471"}, {"drug_name": "Erythropoietin", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cell"}, {"drug_name": "Erythropoietin", "type": "general", "preview": ". Epoetin alfa serves to restore erythropoietin deficiency in pathological and other clinical conditions where normal production of erythropoietin is impaired or compromised. In anemic patients with c"}], "num_chunks": 5}}
{"drug_name": "Salmon calcitonin", "question": "What is Salmon calcitonin?", "ground_truth_answer": "Salmon calcitonin is a synthetic peptide, 32 residues long, formulated as a nasal spray.", "ground_truth_context": {"Name": "Salmon calcitonin", "Description": "Synthetic peptide, 32 residues long formulated as a nasal spray.", "MoA": "Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.", "Targets": "calcitonin receptor (found primarily in osteoclasts)", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Salmon calcitonin is a hormone that is produced by the thyroid gland.", "rag_full_output": {"answer": "Salmon calcitonin is a hormone that is produced by the thyroid gland.", "drug_extracted": "Salmon calcitonin", "chunks_used": [{"drug_name": "Salmon calcitonin", "type": "general", "preview": ". It also promotes the renal excretion of ions such as calcium, phosphate, sodium, magnesium, and potassium by decreasing tubular reabsorption. In consequence, there is an increase in the jejunal secr"}], "num_chunks": 1}}
{"drug_name": "Salmon calcitonin", "question": "What is the mechanism of action of Salmon calcitonin?", "ground_truth_answer": "Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.", "ground_truth_context": {"Name": "Salmon calcitonin", "Description": "Synthetic peptide, 32 residues long formulated as a nasal spray.", "MoA": "Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.", "Targets": "calcitonin receptor (found primarily in osteoclasts)", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.", "rag_full_output": {"answer": "Calcitonin inhibits osteoclast-mediated bone resorption through the regulation of the number and activity of osteoclasts.", "drug_extracted": "calcitonin", "chunks_used": [{"drug_name": "Human calcitonin", "type": "general", "preview": ". ENZYMES: BE0000391 BE0001078 BE0004461. METABOLISM: The kidneys account for two-thirds of the metabolism of calcitonin and generate low molecular weight forms. At a subcellular level, it has been ob"}, {"drug_name": "Human calcitonin", "type": "general", "preview": "TYPE: biotech. CREATED: 2010-09-14. UPDATED: 2020-06-12. GROUPS: approved investigational. DESCRIPTION: Calcitonin was first discovered in isolated parathyroid tissue as a substance with a serum-calci"}, {"drug_name": "Salmon calcitonin", "type": "general", "preview": ". Calcitonin can be used in patients with azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves. Also for the treatment of post-menopausal osteoporosis i"}, {"drug_name": "Human calcitonin", "type": "general", "preview": ". MECHANISM-OF-ACTION: Calcitonin inhibits osteoclast-mediated bone resorption through the regulation of the number and activity of osteoclasts.[A32098] The action of human calcitonin on osteoclasts i"}, {"drug_name": "Human calcitonin", "type": "general", "preview": ". Some reports indicate a calcitonin-driven reduction of phosphate plasma concentration which is thought to be related to increased excretion of phosphate. Calcitonin can increase excretion of calcium"}], "num_chunks": 5}}
{"drug_name": "Salmon calcitonin", "question": "What are the primary targets of Salmon calcitonin?", "ground_truth_answer": "The primary target of Salmon calcitonin is the calcitonin receptor, found primarily in osteoclasts.", "ground_truth_context": {"Name": "Salmon calcitonin", "Description": "Synthetic peptide, 32 residues long formulated as a nasal spray.", "MoA": "Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.", "Targets": "calcitonin receptor (found primarily in osteoclasts)", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Human calcitonin is indicated for the treatment of Paget's disease in the cases where the use of salmon calcitonin may provoke the generation of high-titer of antibodies.", "rag_full_output": {"answer": "Human calcitonin is indicated for the treatment of Paget's disease in the cases where the use of salmon calcitonin may provoke the generation of high-titer of antibodies.", "drug_extracted": "calcitonin", "chunks_used": [{"drug_name": "Human calcitonin", "type": "general", "preview": ". ENZYMES: BE0000391 BE0001078 BE0004461. METABOLISM: The kidneys account for two-thirds of the metabolism of calcitonin and generate low molecular weight forms. At a subcellular level, it has been ob"}, {"drug_name": "Human calcitonin", "type": "general", "preview": "TYPE: biotech. CREATED: 2010-09-14. UPDATED: 2020-06-12. GROUPS: approved investigational. DESCRIPTION: Calcitonin was first discovered in isolated parathyroid tissue as a substance with a serum-calci"}, {"drug_name": "Human calcitonin", "type": "general", "preview": ". INDICATION: Human calcitonin is indicated for the treatment of Paget's disease in the cases where the use of salmon calcitonin may provoke the generation of high-titer of antibodies.[A32100] Paget's"}, {"drug_name": "Human calcitonin", "type": "general", "preview": ". MECHANISM-OF-ACTION: Calcitonin inhibits osteoclast-mediated bone resorption through the regulation of the number and activity of osteoclasts.[A32098] The action of human calcitonin on osteoclasts i"}, {"drug_name": "Salmon calcitonin", "type": "general", "preview": ". It also promotes the renal excretion of ions such as calcium, phosphate, sodium, magnesium, and potassium by decreasing tubular reabsorption. In consequence, there is an increase in the jejunal secr"}], "num_chunks": 5}}
{"drug_name": "Salmon calcitonin", "question": "How many residues long is the Salmon calcitonin peptide?", "ground_truth_answer": "Salmon calcitonin is a synthetic peptide 32 residues long.", "ground_truth_context": {"Name": "Salmon calcitonin", "Description": "Synthetic peptide, 32 residues long formulated as a nasal spray.", "MoA": "Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.", "Targets": "calcitonin receptor (found primarily in osteoclasts)", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Salmon calcitonin is a synthetic peptide 32 residues long.", "rag_full_output": {"answer": "The Salmon calcitonin peptide has 32 amino acids.", "drug_extracted": "calcitonin", "chunks_used": [{"drug_name": "Human calcitonin", "type": "general", "preview": "TYPE: biotech. CREATED: 2010-09-14. UPDATED: 2020-06-12. GROUPS: approved investigational. DESCRIPTION: Calcitonin was first discovered in isolated parathyroid tissue as a substance with a serum-calci"}, {"drug_name": "Salmon calcitonin", "type": "general", "preview": ". It also promotes the renal excretion of ions such as calcium, phosphate, sodium, magnesium, and potassium by decreasing tubular reabsorption. In consequence, there is an increase in the jejunal secr"}, {"drug_name": "Human calcitonin", "type": "general", "preview": ". This characteristic happens because of a high tendency to aggregate, and thus, human calcitonin is used just in cases where the usage of salmon calcitonin generated the formation of antibodies.[A321"}, {"drug_name": "Human calcitonin", "type": "general", "preview": ". ENZYMES: BE0000391 BE0001078 BE0004461. METABOLISM: The kidneys account for two-thirds of the metabolism of calcitonin and generate low molecular weight forms. At a subcellular level, it has been ob"}, {"drug_name": "Human calcitonin", "type": "general", "preview": ". INDICATION: Human calcitonin is indicated for the treatment of Paget's disease in the cases where the use of salmon calcitonin may provoke the generation of high-titer of antibodies.[A32100] Paget's"}], "num_chunks": 5}}
{"drug_name": "Interferon alfa-n3", "question": "What is Interferon alfa-n3?", "ground_truth_answer": "Interferon alfa-n3 is purified, natural human interferon alpha proteins consisting of 3 forms or polymorphisms (2a, 2b, and 2c), with 166 residues, some of which are glycosylated, and a molecular weight ranging from 16 kD to 27 kD.", "ground_truth_context": {"Name": "Interferon alfa-n3", "Description": "Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, and Stat2.", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Interferon alfa-n3 upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens.", "rag_full_output": {"answer": "Interferon alfa-n3 upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens.", "drug_extracted": "Interferon alfa-n3", "chunks_used": [{"drug_name": "Interferon alfa-n3", "type": "general", "preview": ". The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral protei"}], "num_chunks": 1}}
{"drug_name": "Interferon alfa-n3", "question": "Which receptors does Interferon alpha bind to?", "ground_truth_answer": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c).", "ground_truth_context": {"Name": "Interferon alfa-n3", "Description": "Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, and Stat2.", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c)", "rag_full_output": {"answer": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c)", "drug_extracted": "Interferon alpha", "chunks_used": [{"drug_name": "Interferon alfa-2a", "type": "general", "preview": ". MECHANISM-OF-ACTION: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These tran"}, {"drug_name": "Interferon alfa-2b", "type": "general", "preview": ". MECHANISM-OF-ACTION: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which upon dimerization activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transp"}, {"drug_name": "Interferon alfa-n3", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or pol"}, {"drug_name": "Interferon alfa-n1", "type": "general", "preview": ". These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimeriz"}, {"drug_name": "Human interferon omega-1", "type": "general", "preview": ". MECHANISM-OF-ACTION: Independent studies demonstrate that interferon omega binds to the alpha/beta receptor, but not the interferon gamma receptor.. PHARMACODYNAMICS: Human interferon omega 1 (IFN-o"}], "num_chunks": 5}}
{"drug_name": "Interferon alfa-n3", "question": "What happens after type I interferon receptors are activated by Interferon alpha binding?", "ground_truth_answer": "Upon dimerization, the receptors activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2), which then transphosphorylate themselves and phosphorylate the receptors.", "ground_truth_context": {"Name": "Interferon alfa-n3", "Description": "Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, and Stat2.", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Upon dimerization, the receptors activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2), which then transphosphorylate themselves and phosphorylate the receptors.", "rag_full_output": {"answer": "After type I interferon receptors are activated by Interferon alpha binding, they dimerize and activate multiple (~100) immunomodulatory and antiviral proteins.", "drug_extracted": "Interferon alpha", "chunks_used": [{"drug_name": "Interferon alfa-2a", "type": "general", "preview": ". MECHANISM-OF-ACTION: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These tran"}, {"drug_name": "Interferon alfa-2b", "type": "general", "preview": ". MECHANISM-OF-ACTION: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which upon dimerization activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transp"}, {"drug_name": "Interferon alfacon-1", "type": "general", "preview": ". Prior to final purification, Interferon alfacon-1 is allowed to oxidize to its native state, and its final purity is achieved by sequential passage over a series of chromatography columns. This prot"}, {"drug_name": "Interferon alfa-n3", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or pol"}, {"drug_name": "Interferon alfa-n1", "type": "general", "preview": ". These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimeriz"}], "num_chunks": 5}}
{"drug_name": "Interferon alfa-n3", "question": "What are the specific targets of Interferon alfa-n3 in its mechanism of action?", "ground_truth_answer": "The specific targets are Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, and Stat2.", "ground_truth_context": {"Name": "Interferon alfa-n3", "Description": "Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, and Stat2.", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Interferon alfa-n3 upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin, neopterin and protein kinase R.", "rag_full_output": {"answer": "Interferon alfa-n3 upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin, neopterin and protein kinase R.", "drug_extracted": "Interferon alfa-n3", "chunks_used": [{"drug_name": "Interferon alfa-n3", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or pol"}, {"drug_name": "Interferon alfa-n3", "type": "general", "preview": ". The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral protei"}], "num_chunks": 2}}
{"drug_name": "Interferon alfa-n3", "question": "How many forms or polymorphisms does Interferon alfa-n3 consist of?", "ground_truth_answer": "Interferon alfa-n3 consists of 3 forms or polymorphisms including 2a, 2b and 2c.", "ground_truth_context": {"Name": "Interferon alfa-n3", "Description": "Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, and Stat2.", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c).", "rag_full_output": {"answer": "Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c).", "drug_extracted": "Interferon alfa-n3", "chunks_used": [{"drug_name": "Interferon alfa-n3", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or pol"}], "num_chunks": 1}}
{"drug_name": "Pegfilgrastim", "question": "What is Pegfilgrastim?", "ground_truth_answer": "Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim.", "ground_truth_context": {"Name": "Pegfilgrastim", "Description": "Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Due to a longer half-life and slower elimination rate than filgrastim, pegfilgrastim requires less frequent dosing than filgrastim; however, pegfilgrastim has a comparable pharmacological activity to filgrastim and binds to the G-CSF receptor to stimulate the proliferation, differentiation, and activation of neutrophils. First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection.", "MoA": "Pegfilgrastim mimics the biological actions of G-CSF and binds to the G-CSF receptor expressed on cells of myeloid lineage, such as granulocytic precursors and mature neutrophils. Upon binding of the ligand, G-CSF receptor undergoes a conformational change and activates several downstream signalling pathways including JAK/STAT, PI3K/AKT and MAPK/ERK. These pathways work to increase proliferation and differentiation of granulocyte progenitor cells, induce maturation of the progenitor cells, and enhance survival and function of mature neutrophils.", "Targets": "G-CSF receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Pegfilgrastim is a long-acting form of filgrastim with an extended serum half-life and reduced renal clearance.", "rag_full_output": {"answer": "Pegfilgrastim is a long-acting form of filgrastim with an extended serum half-life and reduced renal clearance.", "drug_extracted": "pegfilgrastim", "chunks_used": [{"drug_name": "Pegfilgrastim", "type": "general", "preview": ", Pegfilgrastim is a long-acting form of filgrastim with an extended serum half-life and reduced renal clearance.[A187607] Although it is more slowly absorbed than filgrastim, self-regulation of pegfi"}, {"drug_name": "Pegfilgrastim", "type": "general", "preview": ". It is typically administered via a subcutaneous injection. There are several pegfilgrastim biosimilars (Fulphila, Pelgraz or Lapelga, Pelmeg, Udenyca, Ziextenzo, Grasustek, Fylnetra, Stimufend) by H"}, {"drug_name": "Pegfilgrastim", "type": "general", "preview": ", pegfilgrastim has a comparable pharmacological activity to filgrastim and binds to the G-CSF receptor to stimulate the proliferation, differentiation, and activation of neutrophils.[A187607] First d"}, {"drug_name": "Pegfilgrastim", "type": "general", "preview": ". ROUTE-OF-ELIMINATION: The polyethylene glycol moiety limits the renal clearance by glomerular filtration of pegfilgrastim, making neutrophil-mediated clearance as the predominant route of eliminatio"}], "num_chunks": 4}}
{"drug_name": "Pegfilgrastim", "question": "What is Pegfilgrastim approved for?", "ground_truth_answer": "Pegfilgrastim is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with non-myeloid cancer receiving myelosuppressive anti-cancer treatment.", "ground_truth_context": {"Name": "Pegfilgrastim", "Description": "Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Due to a longer half-life and slower elimination rate than filgrastim, pegfilgrastim requires less frequent dosing than filgrastim; however, pegfilgrastim has a comparable pharmacological activity to filgrastim and binds to the G-CSF receptor to stimulate the proliferation, differentiation, and activation of neutrophils. First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection.", "MoA": "Pegfilgrastim mimics the biological actions of G-CSF and binds to the G-CSF receptor expressed on cells of myeloid lineage, such as granulocytic precursors and mature neutrophils. Upon binding of the ligand, G-CSF receptor undergoes a conformational change and activates several downstream signalling pathways including JAK/STAT, PI3K/AKT and MAPK/ERK. These pathways work to increase proliferation and differentiation of granulocyte progenitor cells, induce maturation of the progenitor cells, and enhance survival and function of mature neutrophils.", "Targets": "G-CSF receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Pegfilgrastim is a long-acting form of filgrastim with an extended serum half-life and reduced renal clearance.", "rag_full_output": {"answer": "Pegfilgrastim is a long-acting form of filgrastim with an extended serum half-life and reduced renal clearance.", "drug_extracted": "pegfilgrastim", "chunks_used": [{"drug_name": "Pegfilgrastim", "type": "general", "preview": ". It is typically administered via a subcutaneous injection. There are several pegfilgrastim biosimilars (Fulphila, Pelgraz or Lapelga, Pelmeg, Udenyca, Ziextenzo, Grasustek, Fylnetra, Stimufend) by H"}, {"drug_name": "Pegfilgrastim", "type": "general", "preview": ", pegfilgrastim has a comparable pharmacological activity to filgrastim and binds to the G-CSF receptor to stimulate the proliferation, differentiation, and activation of neutrophils.[A187607] First d"}, {"drug_name": "Pegfilgrastim", "type": "general", "preview": ", Pegfilgrastim is a long-acting form of filgrastim with an extended serum half-life and reduced renal clearance.[A187607] Although it is more slowly absorbed than filgrastim, self-regulation of pegfi"}], "num_chunks": 3}}
{"drug_name": "Pegfilgrastim", "question": "What is the mechanism of action of Pegfilgrastim?", "ground_truth_answer": "Pegfilgrastim mimics the biological actions of G-CSF and binds to the G-CSF receptor expressed on cells of myeloid lineage to stimulate the proliferation, differentiation, and activation of neutrophils.", "ground_truth_context": {"Name": "Pegfilgrastim", "Description": "Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Due to a longer half-life and slower elimination rate than filgrastim, pegfilgrastim requires less frequent dosing than filgrastim; however, pegfilgrastim has a comparable pharmacological activity to filgrastim and binds to the G-CSF receptor to stimulate the proliferation, differentiation, and activation of neutrophils. First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection.", "MoA": "Pegfilgrastim mimics the biological actions of G-CSF and binds to the G-CSF receptor expressed on cells of myeloid lineage, such as granulocytic precursors and mature neutrophils. Upon binding of the ligand, G-CSF receptor undergoes a conformational change and activates several downstream signalling pathways including JAK/STAT, PI3K/AKT and MAPK/ERK. These pathways work to increase proliferation and differentiation of granulocyte progenitor cells, induce maturation of the progenitor cells, and enhance survival and function of mature neutrophils.", "Targets": "G-CSF receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Pegfilgrastim is a long-acting form of filgrastim with an extended serum half-life and reduced renal clearance.", "rag_full_output": {"answer": "Pegfilgrastim is a long-acting form of filgrastim with an extended serum half-life and reduced renal clearance.", "drug_extracted": "pegfilgrastim", "chunks_used": [{"drug_name": "Pegfilgrastim", "type": "general", "preview": ", pegfilgrastim has a comparable pharmacological activity to filgrastim and binds to the G-CSF receptor to stimulate the proliferation, differentiation, and activation of neutrophils.[A187607] First d"}, {"drug_name": "Pegfilgrastim", "type": "general", "preview": ", Pegfilgrastim is a long-acting form of filgrastim with an extended serum half-life and reduced renal clearance.[A187607] Although it is more slowly absorbed than filgrastim, self-regulation of pegfi"}, {"drug_name": "Pegfilgrastim", "type": "general", "preview": ". ROUTE-OF-ELIMINATION: The polyethylene glycol moiety limits the renal clearance by glomerular filtration of pegfilgrastim, making neutrophil-mediated clearance as the predominant route of eliminatio"}, {"drug_name": "Pegfilgrastim", "type": "general", "preview": ". It is typically administered via a subcutaneous injection. There are several pegfilgrastim biosimilars (Fulphila, Pelgraz or Lapelga, Pelmeg, Udenyca, Ziextenzo, Grasustek, Fylnetra, Stimufend) by H"}], "num_chunks": 4}}
{"drug_name": "Pegfilgrastim", "question": "What is the primary target of Pegfilgrastim?", "ground_truth_answer": "The primary target of Pegfilgrastim is the G-CSF receptor.", "ground_truth_context": {"Name": "Pegfilgrastim", "Description": "Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Due to a longer half-life and slower elimination rate than filgrastim, pegfilgrastim requires less frequent dosing than filgrastim; however, pegfilgrastim has a comparable pharmacological activity to filgrastim and binds to the G-CSF receptor to stimulate the proliferation, differentiation, and activation of neutrophils. First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection.", "MoA": "Pegfilgrastim mimics the biological actions of G-CSF and binds to the G-CSF receptor expressed on cells of myeloid lineage, such as granulocytic precursors and mature neutrophils. Upon binding of the ligand, G-CSF receptor undergoes a conformational change and activates several downstream signalling pathways including JAK/STAT, PI3K/AKT and MAPK/ERK. These pathways work to increase proliferation and differentiation of granulocyte progenitor cells, induce maturation of the progenitor cells, and enhance survival and function of mature neutrophils.", "Targets": "G-CSF receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Pegfilgrastim has a comparable pharmacological activity to filgrastim and binds to the G-CSF receptor to stimulate the proliferation, differentiation, and activation of neutrophils.", "rag_full_output": {"answer": "Pegfilgrastim has a comparable pharmacological activity to filgrastim and binds to the G-CSF receptor to stimulate the proliferation, differentiation, and activation of neutrophils.", "drug_extracted": "pegfilgrastim", "chunks_used": [{"drug_name": "Pegfilgrastim", "type": "general", "preview": ". It is typically administered via a subcutaneous injection. There are several pegfilgrastim biosimilars (Fulphila, Pelgraz or Lapelga, Pelmeg, Udenyca, Ziextenzo, Grasustek, Fylnetra, Stimufend) by H"}, {"drug_name": "Pegfilgrastim", "type": "general", "preview": ", pegfilgrastim has a comparable pharmacological activity to filgrastim and binds to the G-CSF receptor to stimulate the proliferation, differentiation, and activation of neutrophils.[A187607] First d"}, {"drug_name": "Pegfilgrastim", "type": "general", "preview": ", Pegfilgrastim is a long-acting form of filgrastim with an extended serum half-life and reduced renal clearance.[A187607] Although it is more slowly absorbed than filgrastim, self-regulation of pegfi"}], "num_chunks": 3}}
{"drug_name": "Pegfilgrastim", "question": "How is Pegfilgrastim typically administered?", "ground_truth_answer": "Pegfilgrastim is typically administered via a subcutaneous injection.", "ground_truth_context": {"Name": "Pegfilgrastim", "Description": "Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Due to a longer half-life and slower elimination rate than filgrastim, pegfilgrastim requires less frequent dosing than filgrastim; however, pegfilgrastim has a comparable pharmacological activity to filgrastim and binds to the G-CSF receptor to stimulate the proliferation, differentiation, and activation of neutrophils. First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection.", "MoA": "Pegfilgrastim mimics the biological actions of G-CSF and binds to the G-CSF receptor expressed on cells of myeloid lineage, such as granulocytic precursors and mature neutrophils. Upon binding of the ligand, G-CSF receptor undergoes a conformational change and activates several downstream signalling pathways including JAK/STAT, PI3K/AKT and MAPK/ERK. These pathways work to increase proliferation and differentiation of granulocyte progenitor cells, induce maturation of the progenitor cells, and enhance survival and function of mature neutrophils.", "Targets": "G-CSF receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Pegfilgrastim is typically administered via a subcutaneous injection.", "rag_full_output": {"answer": "Pegfilgrastim is typically administered via a subcutaneous injection.", "drug_extracted": "pegfilgrastim", "chunks_used": [{"drug_name": "Pegfilgrastim", "type": "general", "preview": ". It is typically administered via a subcutaneous injection. There are several pegfilgrastim biosimilars (Fulphila, Pelgraz or Lapelga, Pelmeg, Udenyca, Ziextenzo, Grasustek, Fylnetra, Stimufend) by H"}, {"drug_name": "Pegfilgrastim", "type": "general", "preview": ". ABSORPTION: Pegfilgrastim has a lower absolute bioavailability than filgrastim following subcutaneous administration. The absorption of pegfilgrastim is largely dependent on the lymphatic system due"}, {"drug_name": "Pegfilgrastim", "type": "general", "preview": ", Pegfilgrastim is a long-acting form of filgrastim with an extended serum half-life and reduced renal clearance.[A187607] Although it is more slowly absorbed than filgrastim, self-regulation of pegfi"}], "num_chunks": 3}}
{"drug_name": "Sargramostim", "question": "What is Sargramostim?", "ground_truth_answer": "Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast, which is a glycoprotein of 127 residues.", "ground_truth_context": {"Name": "Sargramostim", "Description": "Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.", "MoA": "Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils", "Targets": "Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R)", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in.", "rag_full_output": {"answer": "Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast.", "drug_extracted": "Sargramostim", "chunks_used": [{"drug_name": "Sargramostim", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2022-12-06. GROUPS: approved investigational. DESCRIPTION: Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) ex"}, {"drug_name": "Sargramostim", "type": "general", "preview": ". ATC-CODES: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Colony stimulating factors IMMUNOSTIMULANTS. PHARMACODYNAMICS: Sargramostim is used in the treatment of bone marrow transplant recipients or tho"}], "num_chunks": 2}}
{"drug_name": "Sargramostim", "question": "What is the mechanism of action of Sargramostim?", "ground_truth_answer": "Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway.", "ground_truth_context": {"Name": "Sargramostim", "Description": "Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.", "MoA": "Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils", "Targets": "Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R)", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway.", "rag_full_output": {"answer": "Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway.", "drug_extracted": "sargramostim", "chunks_used": [{"drug_name": "Sargramostim", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2022-12-06. GROUPS: approved investigational. DESCRIPTION: Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) ex"}, {"drug_name": "Sargramostim", "type": "general", "preview": ". ATC-CODES: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Colony stimulating factors IMMUNOSTIMULANTS. PHARMACODYNAMICS: Sargramostim is used in the treatment of bone marrow transplant recipients or tho"}], "num_chunks": 2}}
{"drug_name": "Sargramostim", "question": "What receptor does Sargramostim target?", "ground_truth_answer": "Sargramostim targets the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R).", "ground_truth_context": {"Name": "Sargramostim", "Description": "Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.", "MoA": "Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils", "Targets": "Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R)", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway.", "rag_full_output": {"answer": "Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway.", "drug_extracted": "Sargramostim", "chunks_used": [{"drug_name": "Sargramostim", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2022-12-06. GROUPS: approved investigational. DESCRIPTION: Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) ex"}], "num_chunks": 1}}
{"drug_name": "Sargramostim", "question": "What is the result of the signal transduction pathway stimulated by Sargramostim?", "ground_truth_answer": "This leads to the production of hemopoietic cells and neutrophils.", "ground_truth_context": {"Name": "Sargramostim", "Description": "Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.", "MoA": "Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils", "Targets": "Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R)", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "I can only answer drug-related scientific questions.", "rag_full_output": {"answer": "I can only answer drug-related scientific questions.", "drug_extracted": "NONE", "chunks_used": [], "num_chunks": 0}}
{"drug_name": "Peginterferon alfa-2b", "question": "What is Peginterferon alfa-2b?", "ground_truth_answer": "Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C.", "ground_truth_context": {"Name": "Peginterferon alfa-2b", "Description": "Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Its use has largely declined since newer interferon-free antiviral therapies have been developed, and it is no longer recommended by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) for the treatment of Hepatitis C. It is available as a variable dose injectable product (tradename Pegintron) and was approved in 2001 by the FDA.", "MoA": "Peginterferon alfa-2b is derived from recombinant human interferon's alfa-2b moeity. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response. Peginterferon alfa-2b may also activate the nuclear factor \nR\nB pathway.", "Targets": "human type 1 interferon receptors", "Physical_State": "variable dose injectable product", "Interactions": "Peginterferon alfa-2b is indicated for combination with Ribavirin (DB00811) and a NS3/4A protease inhibitor for genotype 1, or without a NS3/4A protease inhibitor for genotypes 2-6.", "Formula": "N/A"}, "rag_answer": "Peginterferon alfa-2b is a form of recombinant interferon used as part of combination.", "rag_full_output": {"answer": "Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).", "drug_extracted": "peginterferon alfa-2", "chunks_used": [{"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic H"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to"}, {"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000661, BE0000385. DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Upadacitinib, Trazodone, Blinatumomab, Zaltoprofen, Tacrine, Triflusal (...and 85"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000661, BE0000385. DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Upadacitinib, Blinatumomab, Ethyl chloride, Tacrine, Triflusal, Doxepin (...and 6"}, {"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": ". Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Use of P"}], "num_chunks": 5}}
{"drug_name": "Peginterferon alfa-2b", "question": "What is the mechanism of action of Peginterferon alfa-2b?", "ground_truth_answer": "Peginterferon alfa-2b binds to and activates human type 1 interferon receptors causing them to dimerize, which activates the JAK/STAT pathway and may also activate the nuclear factor \nR\nB pathway.", "ground_truth_context": {"Name": "Peginterferon alfa-2b", "Description": "Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Its use has largely declined since newer interferon-free antiviral therapies have been developed, and it is no longer recommended by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) for the treatment of Hepatitis C. It is available as a variable dose injectable product (tradename Pegintron) and was approved in 2001 by the FDA.", "MoA": "Peginterferon alfa-2b is derived from recombinant human interferon's alfa-2b moeity. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response. Peginterferon alfa-2b may also activate the nuclear factor \nR\nB pathway.", "Targets": "human type 1 interferon receptors", "Physical_State": "variable dose injectable product", "Interactions": "Peginterferon alfa-2b is indicated for combination with Ribavirin (DB00811) and a NS3/4A protease inhibitor for genotype 1, or without a NS3/4A protease inhibitor for genotypes 2-6.", "Formula": "N/A"}, "rag_answer": "Peginterferon alfa-2b binds to and activates human type 1 interferon receptors causing them to dimerize, which activates the JAK/STAT pathway and may also activate the nuclear factor \nR\nB pathway.", "rag_full_output": {"answer": "Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors", "drug_extracted": "peginterferon alfa-2", "chunks_used": [{"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000661, BE0000385. DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Upadacitinib, Trazodone, Blinatumomab, Zaltoprofen, Tacrine, Triflusal (...and 85"}, {"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic H"}, {"drug_name": "Ropeginterferon alfa-2b", "type": "general", "preview": ". PV results in clonal hematopoietic stem cells, such that they form endogenous erythroid colonies (EECs) _in vitro_.[A242000] Interferon alfa-2b has been used for decades in PV despite the lack of fo"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to"}, {"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": ". Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Use of P"}], "num_chunks": 5}}
{"drug_name": "Peginterferon alfa-2b", "question": "What are the targets of Peginterferon alfa-2b?", "ground_truth_answer": "The targets of Peginterferon alfa-2b are human type 1 interferon receptors.", "ground_truth_context": {"Name": "Peginterferon alfa-2b", "Description": "Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Its use has largely declined since newer interferon-free antiviral therapies have been developed, and it is no longer recommended by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) for the treatment of Hepatitis C. It is available as a variable dose injectable product (tradename Pegintron) and was approved in 2001 by the FDA.", "MoA": "Peginterferon alfa-2b is derived from recombinant human interferon's alfa-2b moeity. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response. Peginterferon alfa-2b may also activate the nuclear factor \nR\nB pathway.", "Targets": "human type 1 interferon receptors", "Physical_State": "variable dose injectable product", "Interactions": "Peginterferon alfa-2b is indicated for combination with Ribavirin (DB00811) and a NS3/4A protease inhibitor for genotype 1, or without a NS3/4A protease inhibitor for genotypes 2-6.", "Formula": "N/A"}, "rag_answer": "The targets of Peginterferon alfa-2b are human type 1 interferon receptors.", "rag_full_output": {"answer": "Peginterferon alfa-2b has the following targets: BE0000661, BE0000385.", "drug_extracted": "peginterferon alfa-2", "chunks_used": [{"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000661, BE0000385. DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Upadacitinib, Trazodone, Blinatumomab, Zaltoprofen, Tacrine, Triflusal (...and 85"}, {"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic H"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000661, BE0000385. DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Upadacitinib, Blinatumomab, Ethyl chloride, Tacrine, Triflusal, Doxepin (...and 6"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to"}, {"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": ". Peginterferon alfa-2b was used alongside [DB00811] with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of therapy. SVR and eradication of HCV infection is associ"}], "num_chunks": 5}}
{"drug_name": "Peginterferon alfa-2b", "question": "What is the physical state and tradename of Peginterferon alfa-2b?", "ground_truth_answer": "Peginterferon alfa-2b is available as a variable dose injectable product (tradename Pegintron).", "ground_truth_context": {"Name": "Peginterferon alfa-2b", "Description": "Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Its use has largely declined since newer interferon-free antiviral therapies have been developed, and it is no longer recommended by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) for the treatment of Hepatitis C. It is available as a variable dose injectable product (tradename Pegintron) and was approved in 2001 by the FDA.", "MoA": "Peginterferon alfa-2b is derived from recombinant human interferon's alfa-2b moeity. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response. Peginterferon alfa-2b may also activate the nuclear factor \nR\nB pathway.", "Targets": "human type 1 interferon receptors", "Physical_State": "variable dose injectable product", "Interactions": "Peginterferon alfa-2b is indicated for combination with Ribavirin (DB00811) and a NS3/4A protease inhibitor for genotype 1, or without a NS3/4A protease inhibitor for genotypes 2-6.", "Formula": "N/A"}, "rag_answer": "Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).", "rag_full_output": {"answer": "Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).", "drug_extracted": "Peginterferon alfa-", "chunks_used": [{"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": ". Peginterferon alfa-2b was used alongside [DB00811] with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of therapy. SVR and eradication of HCV infection is associ"}, {"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic H"}, {"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000661, BE0000385. DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Upadacitinib, Trazodone, Blinatumomab, Zaltoprofen, Tacrine, Triflusal (...and 85"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000661, BE0000385. DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Upadacitinib, Blinatumomab, Ethyl chloride, Tacrine, Triflusal, Doxepin (...and 6"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to"}], "num_chunks": 5}}
{"drug_name": "Peginterferon alfa-2b", "question": "With which drugs is Peginterferon alfa-2b indicated for combination therapy?", "ground_truth_answer": "Peginterferon alfa-2b is indicated for combination with Ribavirin (DB00811) and a NS3/4A protease inhibitor for genotype 1, or without a NS3/4A protease inhibitor for genotypes 2-6.", "ground_truth_context": {"Name": "Peginterferon alfa-2b", "Description": "Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Its use has largely declined since newer interferon-free antiviral therapies have been developed, and it is no longer recommended by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) for the treatment of Hepatitis C. It is available as a variable dose injectable product (tradename Pegintron) and was approved in 2001 by the FDA.", "MoA": "Peginterferon alfa-2b is derived from recombinant human interferon's alfa-2b moeity. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response. Peginterferon alfa-2b may also activate the nuclear factor \nR\nB pathway.", "Targets": "human type 1 interferon receptors", "Physical_State": "variable dose injectable product", "Interactions": "Peginterferon alfa-2b is indicated for combination with Ribavirin (DB00811) and a NS3/4A protease inhibitor for genotype 1, or without a NS3/4A protease inhibitor for genotypes 2-6.", "Formula": "N/A"}, "rag_answer": "Peginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label].", "rag_full_output": {"answer": "Peginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label].", "drug_extracted": "Peginterferon alfa-", "chunks_used": [{"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000661, BE0000385. DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Upadacitinib, Trazodone, Blinatumomab, Zaltoprofen, Tacrine, Triflusal (...and 85"}, {"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": ". Peginterferon alfa-2b was used alongside [DB00811] with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of therapy. SVR and eradication of HCV infection is associ"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": ". STATE: liquid. TARGETS: BE0000661, BE0000385. DRUG-INTERACTIONS: Teriflunomide, Indomethacin, Warfarin, Azacitidine, Upadacitinib, Blinatumomab, Ethyl chloride, Tacrine, Triflusal, Doxepin (...and 6"}, {"drug_name": "Peginterferon alfa-2b", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic H"}, {"drug_name": "Peginterferon alfa-2a", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to"}], "num_chunks": 5}}
{"drug_name": "Asparaginase Escherichia coli", "question": "What is Asparaginase Escherichia coli?", "ground_truth_answer": "Asparaginase derived from _Escherichia coli_ is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia.", "ground_truth_context": {"Name": "Asparaginase Escherichia coli", "Description": "Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It has clinically shown to exhibit antitumor actions in models of leukaemias and is marketed for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It works by depleting levels of asparagine in lymphoblastic leukemic cells, promoting apoptotic cell death.", "MoA": "Asparaginase from _E. coli_ depletes plasma levels of asparagine in leukemic cells by converting L-asparagine to L-aspartic acid and ammonia. This leads to reduced DNA, RNA and protein synthesis, inhibition of cell growth, and activation of apoptotic cell-death mechanisms. Leukemic cells are affected as they lack asparagine synthetase and rely on exogenous asparagine, while normal cells can synthesize it.", "Targets": "L-asparagine", "Physical_State": "Available as intramuscular or intravenous injections", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Asparaginase Escherichia coli is a drug.", "rag_full_output": {"answer": "Asparaginase Escherichia coli is a drug.", "drug_extracted": "asparaginase escherich", "chunks_used": [{"drug_name": "Asparaginase Escherichia coli", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enz"}, {"drug_name": "Asparaginase Escherichia coli", "type": "general", "preview": ". For patients who develop hypersensitivity to _E. coli_-derived formulations of L-asparaginase, the use of PEGylated or non-PEGylated [DB08886] is recommended [A31999].. AVERAGE-MASS: 323.4. MONOISOT"}], "num_chunks": 2}}
{"drug_name": "Asparaginase Escherichia coli", "question": "For what condition is L-asparaginase of _E. coli_ primarily used?", "ground_truth_answer": "L-asparaginase of _E. coli_ is marketed for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen.", "ground_truth_context": {"Name": "Asparaginase Escherichia coli", "Description": "Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It has clinically shown to exhibit antitumor actions in models of leukaemias and is marketed for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It works by depleting levels of asparagine in lymphoblastic leukemic cells, promoting apoptotic cell death.", "MoA": "Asparaginase from _E. coli_ depletes plasma levels of asparagine in leukemic cells by converting L-asparagine to L-aspartic acid and ammonia. This leads to reduced DNA, RNA and protein synthesis, inhibition of cell growth, and activation of apoptotic cell-death mechanisms. Leukemic cells are affected as they lack asparagine synthetase and rely on exogenous asparagine, while normal cells can synthesize it.", "Targets": "L-asparagine", "Physical_State": "Available as intramuscular or intravenous injections", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "L-asparaginase of _E. coli_ is marketed for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen.", "rag_full_output": {"answer": "L-asparaginase of _E. coli_ is primarily used for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen.", "drug_extracted": "L-asparaginase", "chunks_used": [{"drug_name": "Asparaginase Escherichia coli", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enz"}, {"drug_name": "Asparaginase Escherichia coli", "type": "general", "preview": ". For patients who develop hypersensitivity to _E. coli_-derived formulations of L-asparaginase, the use of PEGylated or non-PEGylated [DB08886] is recommended [A31999].. AVERAGE-MASS: 323.4. MONOISOT"}, {"drug_name": "Asparaginase Erwinia chrysanthemi", "type": "general", "preview": "TYPE: biotech. CREATED: 2013-05-27. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _c"}, {"drug_name": "Asparaginase Escherichia coli", "type": "general", "preview": ". While healthy and normal cells are capable of obtaining asparagine via dietary intake or synthesizing the asparagine from aspartate via asparagine synthetase activity, lymphoblastic leukemic cells l"}, {"drug_name": "Asparaginase Erwinia chrysanthemi", "type": "general", "preview": ". coli_-derived asparaginase following an allergic reaction has been safe and effective.[A236359] Asparaginase _Erwinia chrysanthemi_ was first approved by the FDA in November 2011 to treat patients w"}], "num_chunks": 5}}
{"drug_name": "Asparaginase Escherichia coli", "question": "How does Asparaginase Escherichia coli lead to apoptotic cell death in leukemic cells?", "ground_truth_answer": "Therapeutic L-asparaginase from _E. coli_ works by depleting the levels of non-essential amino acid, asparagine, in lymphoblastic leukemic cells thus promoting apoptotic cell death.", "ground_truth_context": {"Name": "Asparaginase Escherichia coli", "Description": "Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It has clinically shown to exhibit antitumor actions in models of leukaemias and is marketed for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It works by depleting levels of asparagine in lymphoblastic leukemic cells, promoting apoptotic cell death.", "MoA": "Asparaginase from _E. coli_ depletes plasma levels of asparagine in leukemic cells by converting L-asparagine to L-aspartic acid and ammonia. This leads to reduced DNA, RNA and protein synthesis, inhibition of cell growth, and activation of apoptotic cell-death mechanisms. Leukemic cells are affected as they lack asparagine synthetase and rely on exogenous asparagine, while normal cells can synthesize it.", "Targets": "L-asparagine", "Physical_State": "Available as intramuscular or intravenous injections", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "L-asparaginase from _E. coli_ works by depleting the levels of non-essential amino acid, asparagine, in lymphoblastic leukemic cells thus promoting apoptotic cell death [A31999].", "rag_full_output": {"answer": "L-asparaginase from _E. coli_ works by depleting the levels of non-essential amino acid, asparagine, in lymphoblastic leukemic cells thus promoting apoptotic cell death [A31999].", "drug_extracted": "Asparaginase Escherich", "chunks_used": [{"drug_name": "Asparaginase Escherichia coli", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enz"}, {"drug_name": "Asparaginase Escherichia coli", "type": "general", "preview": ". While healthy and normal cells are capable of obtaining asparagine via dietary intake or synthesizing the asparagine from aspartate via asparagine synthetase activity, lymphoblastic leukemic cells l"}], "num_chunks": 2}}
{"drug_name": "Asparaginase Escherichia coli", "question": "Why are lymphoblastic leukemic cells particularly susceptible to asparagine depletion?", "ground_truth_answer": "Lymphoblastic leukemic cells lack the asparagine synthetase enzyme and cannot produce asparagine _de novo_, relying on exogenous asparagine for protein synthesis and cell survival.", "ground_truth_context": {"Name": "Asparaginase Escherichia coli", "Description": "Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It has clinically shown to exhibit antitumor actions in models of leukaemias and is marketed for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It works by depleting levels of asparagine in lymphoblastic leukemic cells, promoting apoptotic cell death.", "MoA": "Asparaginase from _E. coli_ depletes plasma levels of asparagine in leukemic cells by converting L-asparagine to L-aspartic acid and ammonia. This leads to reduced DNA, RNA and protein synthesis, inhibition of cell growth, and activation of apoptotic cell-death mechanisms. Leukemic cells are affected as they lack asparagine synthetase and rely on exogenous asparagine, while normal cells can synthesize it.", "Targets": "L-asparagine", "Physical_State": "Available as intramuscular or intravenous injections", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Lymphoblastic leukemic cells lack the asparagine synthetase enzyme and cannot produce asparagine _de novo_, relying on exogenous asparagine for protein synthesis and cell survival.", "rag_full_output": {"answer": "Lymphoblastic leukemic cells lack the asparagine synthetase enzyme and cannot produce asparagine _de novo_.", "drug_extracted": "asparaginase", "chunks_used": [{"drug_name": "Asparaginase Escherichia coli", "type": "general", "preview": ". While healthy and normal cells are capable of obtaining asparagine via dietary intake or synthesizing the asparagine from aspartate via asparagine synthetase activity, lymphoblastic leukemic cells l"}, {"drug_name": "Asparaginase Erwinia chrysanthemi", "type": "general", "preview": ". Asparaginase _Erwinia_ _chrysanthemi_ depletes the source of asparagine for leukemic cells, resulting in the death of leukemic cells.[L149,L34719] In addition to asparagine, asparaginase _Erwinia_ _"}, {"drug_name": "Asparaginase Escherichia coli", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enz"}, {"drug_name": "Asparaginase Erwinia chrysanthemi", "type": "general", "preview": ". INDICATION: Asparaginase _Erwinia chrysanthemi_ is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) and lympho"}, {"drug_name": "Asparaginase Escherichia coli", "type": "general", "preview": ". For patients who develop hypersensitivity to _E. coli_-derived formulations of L-asparaginase, the use of PEGylated or non-PEGylated [DB08886] is recommended [A31999].. AVERAGE-MASS: 323.4. MONOISOT"}], "num_chunks": 5}}
{"drug_name": "Asparaginase Escherichia coli", "question": "What are the available administration routes for L-asparaginase from _E. coli_?", "ground_truth_answer": "It is available as intramuscular or intravenous injections.", "ground_truth_context": {"Name": "Asparaginase Escherichia coli", "Description": "Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It has clinically shown to exhibit antitumor actions in models of leukaemias and is marketed for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It works by depleting levels of asparagine in lymphoblastic leukemic cells, promoting apoptotic cell death.", "MoA": "Asparaginase from _E. coli_ depletes plasma levels of asparagine in leukemic cells by converting L-asparagine to L-aspartic acid and ammonia. This leads to reduced DNA, RNA and protein synthesis, inhibition of cell growth, and activation of apoptotic cell-death mechanisms. Leukemic cells are affected as they lack asparagine synthetase and rely on exogenous asparagine, while normal cells can synthesize it.", "Targets": "L-asparagine", "Physical_State": "Available as intramuscular or intravenous injections", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "L-asparaginase from _E. coli_ is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in adults and children who have developed hypersensitivity to _E. coli_-derived asparaginase.", "rag_full_output": {"answer": "L-asparaginase from _E. coli_ is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in adults and children who have developed hypersensitivity to _E. coli_-derived asparaginase.", "drug_extracted": "L-asparaginase", "chunks_used": [{"drug_name": "Asparaginase Escherichia coli", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved investigational. DESCRIPTION: Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enz"}, {"drug_name": "Asparaginase Escherichia coli", "type": "general", "preview": ". ATC-CODES: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS OTHER ANTINEOPLASTIC AGENTS ANTINEOPLASTIC AGENTS Other antineoplastic agents. PHARMACODYNAMICS: In clinical trials of patients with previously "}, {"drug_name": "Asparaginase Escherichia coli", "type": "general", "preview": ". While healthy and normal cells are capable of obtaining asparagine via dietary intake or synthesizing the asparagine from aspartate via asparagine synthetase activity, lymphoblastic leukemic cells l"}, {"drug_name": "Asparaginase Escherichia coli", "type": "general", "preview": ". coli_ resulted in a cumulative increase in plasma levels. Following intramuscular injection in patients with metastatic cancer and leukemia, peak plasma levels of asparaginase was achieved 14 to 24 "}, {"drug_name": "Asparaginase Erwinia chrysanthemi", "type": "general", "preview": ". INDICATION: Asparaginase _Erwinia chrysanthemi_ is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) and lympho"}], "num_chunks": 5}}
{"drug_name": "Thyrotropin alfa", "question": "What is Thyrotropin alfa used for?", "ground_truth_answer": "Thyrotropin alfa is used in performing certain tests in patients who have or have had thyroid cancer and also along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer.", "ground_truth_context": {"Name": "Thyrotropin alfa", "Description": "Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of adenylate cyclase, displays close structural similarity with the alpha subunit of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.", "MoA": "Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues. This stimulates radioactive iodine uptake for better radiodiagnostic imaging.", "Targets": "Thyrotropin receptors", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Thyrotropin alfa is used in performing certain tests in patients who have or have had thyroid cancer and also along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer.", "rag_full_output": {"answer": "Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer.", "drug_extracted": "thyrotropin alfa", "chunks_used": [{"drug_name": "Thyrotropin alfa", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: vet_approved approved. DESCRIPTION: Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain te"}], "num_chunks": 1}}
{"drug_name": "Thyrotropin alfa", "question": "What is the mechanism of action of Thyrotropin alfa?", "ground_truth_answer": "Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues, stimulating radioactive iodine uptake for better radiodiagnostic imaging.", "ground_truth_context": {"Name": "Thyrotropin alfa", "Description": "Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of adenylate cyclase, displays close structural similarity with the alpha subunit of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.", "MoA": "Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues. This stimulates radioactive iodine uptake for better radiodiagnostic imaging.", "Targets": "Thyrotropin receptors", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues, stimulating radioactive iodine uptake for better radiodiagnostic imaging.", "rag_full_output": {"answer": "Thyrotropin alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues.", "drug_extracted": "thyrotropin alfa", "chunks_used": [{"drug_name": "Thyrotropin alfa", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: vet_approved approved. DESCRIPTION: Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain te"}, {"drug_name": "Thyrotropin alfa", "type": "general", "preview": ". The beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone"}], "num_chunks": 2}}
{"drug_name": "Thyrotropin alfa", "question": "What are the subunits that comprise Thyrotropin alfa?", "ground_truth_answer": "Thyrotropin alfa is comprised of an alpha subunit of 92 amino acid residues and a beta subunit of 112 residues.", "ground_truth_context": {"Name": "Thyrotropin alfa", "Description": "Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of adenylate cyclase, displays close structural similarity with the alpha subunit of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.", "MoA": "Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues. This stimulates radioactive iodine uptake for better radiodiagnostic imaging.", "Targets": "Thyrotropin receptors", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Thyrotropin alfa is comprised of an alpha subunit of 92 amino acid residues and a beta subunit of 112 residues.", "rag_full_output": {"answer": "Thyrotropin alfa is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site.", "drug_extracted": "thyroid hormone receptor", "chunks_used": [{"drug_name": "Thyrotropin alfa", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: vet_approved approved. DESCRIPTION: Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain te"}, {"drug_name": "Thyrotropin alfa", "type": "general", "preview": ". The beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone"}, {"drug_name": "Levothyroxine", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the t"}, {"drug_name": "Levothyroxine", "type": "general", "preview": ". Other minor T<sub>4</sub> metabolites have been identified. [F4636]. ROUTE-OF-ELIMINATION: Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the c"}, {"drug_name": "Levothyroxine", "type": "general", "preview": ". The thyroid hormones have been shown to exert both genomic and non-genomic effects.[A179950] They exert their genomic effects by diffusing into the cell nucleus and binding to thyroid hormone recept"}], "num_chunks": 5}}
{"drug_name": "Thyrotropin alfa", "question": "What is the amino acid sequence of thyrotropin alfa identical to?", "ground_truth_answer": "The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.", "ground_truth_context": {"Name": "Thyrotropin alfa", "Description": "Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of adenylate cyclase, displays close structural similarity with the alpha subunit of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.", "MoA": "Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues. This stimulates radioactive iodine uptake for better radiodiagnostic imaging.", "Targets": "Thyrotropin receptors", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer.", "rag_full_output": {"answer": "Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer.", "drug_extracted": "thyrotropin alfa", "chunks_used": [{"drug_name": "Thyrotropin alfa", "type": "general", "preview": ". The beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone"}, {"drug_name": "Thyrotropin alfa", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: vet_approved approved. DESCRIPTION: Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain te"}, {"drug_name": "Thyrotropin alfa", "type": "general", "preview": ". PHARMACODYNAMICS: Binding of thyrotropin alfa to TSH receptors on normal thyroid epithelial cells or on well-differentiated thyroid cancer tissue stimulates iodine uptake and organification. Thyroge"}], "num_chunks": 3}}
{"drug_name": "Thyrotropin alfa", "question": "What are the targets of Thyrotropin alfa?", "ground_truth_answer": "Thyrotropin alfa targets thyrotropin receptors.", "ground_truth_context": {"Name": "Thyrotropin alfa", "Description": "Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of adenylate cyclase, displays close structural similarity with the alpha subunit of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.", "MoA": "Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues. This stimulates radioactive iodine uptake for better radiodiagnostic imaging.", "Targets": "Thyrotropin receptors", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}, "rag_answer": "Thyrotropin alfa has the following targets: BE0000315, BE0000687.", "rag_full_output": {"answer": "Thyrotropin alfa has the following targets: BE0000315, BE0000687.", "drug_extracted": "thyroid hormone receptor", "chunks_used": [{"drug_name": "Thyroid, porcine", "type": "general", "preview": ". STATE: solid. TARGETS: BE0000315, BE0000687. DRUG-INTERACTIONS: Indalpine, Clocortolone acetate, Warfarin, Esterified estrogens, Trazodone, Metaraminol, Lobeglitazone, Nortriptyline, Dersalazine, Do"}, {"drug_name": "Levothyroxine", "type": "general", "preview": "TYPE: small molecule. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: approved. DESCRIPTION: Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the t"}, {"drug_name": "Thyrotropin alfa", "type": "general", "preview": "TYPE: biotech. CREATED: 2005-06-13. UPDATED: 2023-01-03. GROUPS: vet_approved approved. DESCRIPTION: Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain te"}, {"drug_name": "Levothyroxine", "type": "general", "preview": ". The thyroid hormones have been shown to exert both genomic and non-genomic effects.[A179950] They exert their genomic effects by diffusing into the cell nucleus and binding to thyroid hormone recept"}, {"drug_name": "Levothyroxine", "type": "general", "preview": ". Other minor T<sub>4</sub> metabolites have been identified. [F4636]. ROUTE-OF-ELIMINATION: Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the c"}], "num_chunks": 5}}
